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ABSTRACT  





Methods: A case-control design, cross-sectional study was conducted to evaluate the prevalence of peri-
implantitis among individuals diagnosed with cardiovascular diseases (CVD). Health and CVD history were 
obtained through structured questionnaire. Participants who had at least one implant in function for more than 6 
months were recruited. Individuals without CVD were grouped as "Control', and participants in the "Case" CVD 
group were recruited only when the dental implants were placed prior to CVD diagnosis. Among the "Case" 
group, individuals with peri-implantitis were included in the final analysis only when the per-implantitis onset 
was evidenced radiographically prior to the diagnosis of the CVD. Clinical and radiographic examinations were 
performed; samples of serum, peri-implant crevicular fluid (PICF), and gingival crevicular fluid (GCF) at the 
most severe diseased sites were collected to evaluate the pro-inflammatory cytokine profile. Subgingival plaque 
from the peri-implantitis sulci were analyzed using 16S rRNA next-generation sequencing and real-time qPCR 
technologies. 
Results: A higher prevalence of peri-implantitis (with detectable radiographic bone loss) in the CVD group 
(OR= 1.48, 95% CI= 0.71 to 3.11, p= 0.30) was found. Furthermore, moderate to severe peri-implantitis 
(radiographic bone loss ≥ 2mm) was significantly associated with cardiovascular diseases (OR= 2.18, 95% CI= 
1.02 to 4.67, p=0.04), but was no longer observed after controlling for multiple significant confounding factors. 
The microbial community among the CVD group and peri-implantitis group demonstrated a more divergent 
profile compared to the control and healthy implant group. Predominantly anaerobic microorganisms at the peri-
implantitis niche were associated with deeper pockets and severe bone loss. A higher bacterial counts (gene 
copies) of Prophylomonas gingivalis (P. gingivalis) was observed in the CVD group. Secondly, peri-implantitis 
pockets appeared to harbor higher Fusobacterium nucleatum (F. nucleatum) DNA in a dose-responsive 
relationship with the severity of peri-implant disease. Tannerella forsythia (T. forsythia) was significantly 
higher only in the severe peri-implantitis  (radiographic bone loss> 4 mm). Serum fibrinogen was significantly 
higher in the CVD group and moderate to severe peri-implantitis (radiographic bone loss≥ 2mm) sites when 
compared to the control or healthy implant groups. A similar trend was observed in the serum interleukin (IL)-6, 
tumor necrosis factor (TNF-𝛼), and osteoprotegerin (OPG). PICF TNF-𝛼 was predominantly higher in the CVD 
group. This coincided with the local peri-implant inflammation. Matrix metalloproteinase (MMP)-8, IL-1𝛽, and 
tissue inhibited metalloproteinase (TIMP)-2 displayed fair accuracy in predicting peri-implant disease. The 
sensitivity increased when combined with the bacterial concentration of T. forsythia and F. nucleatum. Finally, 




Conclusions: Moderate to severe peri-implantitis (radiographic bone loss ≥ 2mm) was observed to be a mild 
associative positive risk factor for the development of cardiovascular disease. However, a significant association 
was not observed after multivariable adjustment. Low-grade chronic inflammation around diseased dental 
implants, especially when the disease severity and tissue destruction was increased, may be linked to 
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CAL clinical attachment loss 
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HA hydroxyapatite 
HBP high blood pressure 
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SD standard deviation 
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TC total cholesterol 
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Chapter I: Introduction       
 
Peri-implantitis is a plaque-associated pathological condition occurring in tissue around dental implants 
characterized by inflammation in the peri-implant mucosa and subsequent progressive loss of supporting bone 
(Berglundh et al. 2018). Similarly, peri-implant mucositis presents with soft tissue inflammation in the absence 




Mayfield and Salvi 2018). Collectively, it can be referred to as peri-implant disease, which are the biological 
complications surrounding dental implants and their restorative components induced by the accumulation of a 
bacterial biofilm (Renvert et al. 2018). Conversely, peri-implant health is defined as intact hard and soft tissue 
compartments free of inflammation (Araujo and Lindhe 2018). The prevalence of peri-implantitis largely varied 
from the different cut-off threshold of bone loss (Schwarz et al. 2018). In a recent systematic review, the 
prevalence of peri-implant mucositis and peri-implantitis were estimated to range from 19% to 65% and from 
1% to 47% with a negative relationship with the threshold for bone loss (Derks and Tomasi 2015). 
 
Cardiovascular diseases (CVD) are the leading cause among non-communicable diseases for  global motality 
rates and accounts for one-third of total mortality (World Health Organization 2014). On the basis of NHANES 
2013 to 2016 data, prevalence of CVD (comprising coronary heart disease, heart failure, stroke, and 
hypertension) in adults ≥ 20 years of age is 48.0% overall (121.5 million in 2016) and increases with age in both 
genders. CVD prevalence excluding hypertension is 9.0% overall (Centers for Disease Control and Prevention 
2019). CVD has been linked to  chronic periodontitis based on a significant body of epidemiologic evidence.  
Biologic plausibility related to periodontal bacteremia and mounting systemic inflammatory burden has been 
widely investigated  (Dietrich et al. 2013; Sanz et al. 2020). Similar to chronic periodontitis, the chronic 
inflammation around dental implants was found consistently harboring periopathogenic bacteria (de Waal et al. 
2017; Schwarz et al. 2018) and augmented immune response via the accumulating evidence of increased pro-
inflammatory cytokines at peri-implantitis sites (Duarte et al. 2016; Gürlek et al. 2017). On the basis of 
similarities in microbial profiles and the elevated chronic inflammatory response between periodontitis and peri-
implantitis, a potential link between peri-implantitis and cardiovascular disease was suspected. It has been 
reported that there was a higher prevalence of CVD among individuals with peri-implantitis (Renvert et al. 
2014; Dalago et al. 2017). The prevalence of CVD was statistically significantly associated with one of the 
periodontal pathogens, Prevotella intermedia (P. intermedia), at the peri-implantitis sites (Lachmann et al. 
2013). It was proposed that the chronic inflammation associated with peri-implant disease may induce and 
escalate systemic low-grade inflammation and increase the risk of cardiovascular disease via a similar infectious 
axis between periodontitis and CVD. The purpose of this study was to assess the relationship between peri-






Chapter II: Background of cardiovascular and peri-implant diseases    
 
A. Disease Burden of Cardiovascular Disease 
 
The highest global burden of non-communicable disease (NCDs) arises from cardiovascular diseases (CVD), 
which are responsible for 17.9 million deaths (a third of total mortality) and 45% of NCD-induced mortality 
(Roth et al. 2017). Ischemic heart disease, stroke, hypertensive heart disease, rheumatic heart disease, 
cardiomyopathy and arterial fibrillation cause over 95% of CVD-related deaths (Roth et al. 2015). 
Cardiovascular diseases (CVD) are the leading cause of death in the United States. Heart disease and stroke 
were the first and fourth in the ranking of the 10 leading causes of death (Murphy et al. 2018). It was also the 
most expensive chronic condition generating not only overall medical expenditures but also the loss of 
workplace productivity estimated at $207 billion each year in the United States (Goetzel et al. 2017). The direct 
healthcare costs of CVD are projected to triple from $273 billion in 2010 to $818 billion in 2030; and the 
indirect costs associated with lost productivity was projected to increase from $172 billion to $276 billion 
(Fonarow et al. 2015). According to a recent systematic metric measuring the age-related morbidity and 
mortality at population level, using the data from the Global Burden of Diseases, Injuries, and Risk Factors 
Study, 92 diseases were identified as age related, accounting for 51.3% of all global burden among adults in 
2017(Chang et al. 2019). CVD is considered the most important age-related disease, which was defined as a 
disease with incidence rate increasing quadratically with age, and measured with their age-related burden, 
namely the sum of disability-adjusted life-years (DALYs). The rate of age-related burden ranged from 137.8 
DALYs per 100 adults in high socio-demographic index (SDI) countries to 265.9 DALYs in low SDI countries. 
CVD accounted for 38.4% of the age-related disease burden; and ischemic heart disease, intracerebral 
hemorrhage (stroke) were the two leading age-related diseases with most deaths and DALYs globally (Kyu et 
al. 2018). 
 
B. Prevalence of Cardiovascular Disease 
 
Annually, the American Heart Association (AHA) in conjunction with the National Institutes of Health (NIH) 
publishes current statistics related to heart disease, stroke, and the cardiovascular risk factors (Virani et al. 




conditions and is collectively termed the "Total Cardiovascular Disease (CVD)" including stroke, congenital 
heart disease, rhythm disorders, subclinical atherosclerosis, coronary heart disease, heart failure, valvular 
disease, venous disease, and peripheral artery disease. The AHA statistics updated in 2020 first focused on the 
basis of NHANES 2013-2016 data. The prevalence of the Total CVD (Comprising CHD, HF, stroke and 
hypertension) in adults (≥ 20 years of age) is 48% (Virani et al. 2020). CVD prevalence excluding hypertension 
(coronary heart disease (CHD), heart failure (HF), and stroke only) is 9% overall (National Center for Health 
Statistics 2017). More recently, the 2017 National Health Interview Survey showed the age-adjusted prevalence 
of all types of heart disease (HD) was 10.6%; and the age-adjusted prevalence of HD, coronary artery disease 
(CAD), hypertension, and stroke was higher in men (11.8%, 7.2%, 26%, and 3.3%, respectively) than women 
(9.5%, 4.2%, 23.1%, and 2.5%, respectively)(Blackwell and Villarroel 2018).  
 
C. Risk factors for Cardiovascular Disease 
 
The CVD-associated risk factors have been prodigiously investigated for decades. A recent study calculated the 
Global Burden of Disease (GBD) among US adults and found that CVD is attributable to dietary risks, high 
blood pressure (HBP), high Body Mass Index (BMI), high total cholesterol (TC) level, high fasting plasma 
glucose (FPG) level, tobacco smoking, and low levels of physical activity(in decreasing order of 
contribution)(Virani et al. 2020). Unfortunately, 99% of the US adult population has at least one of the seven 
cardiovascular health risks. The combined contribution of these risk factors escalated medical spending by 
213.6% per person per year(Goetzel et al. 2017). The prevalence of uncontrolled risk factors for CVD among 
adults in US was estimated at 47% with 1 of the 3 well-established key risk factors(HBP, high cholesterol, and 
smoking) (Fryar et al. 2012). Another study identified HBP as the most important single preventable risk factor 
for cardiovascular mortality in US and was responsible for 45% of all cardiovascular deaths. Additional risk 
factors for cardiovascular mortality were insulin resistance, overweight/obesity, low physical activity, high low-
density lipoprotein cholesterol (LDL-C), smoking, high dietary salt and transfatty acids, and low dietary omega-
3 fatty acids (Danaei et al. 2009). Other than traditional CVD risk factors, chronic kidney disease (CKD), 
systolic blood pressure (SBP) variability, migraine, severe mental illness, systemic lupus erythematous, use of 
corticosteroid or antipsychotic medications, early-age menopause, HIV, type 1 diabetes mellitus (DM), 
socioeconomic deprivation, and erectile dysfunction were reported as  non-traditional CVD risk factors 





In recent years, the AHA has defined cardiovascular health based on 7 risk factors-Life' Simple 7 (American 
Heart Association), which include key health behaviors (smoking, physical activity, diet, and weight) and core 
health factors (cholesterol, blood pressure and glucose control). People with at least five factors fulfilling the 
ideal Life's Simple 7 metric had reduced risk for heart-related death by 78% compared to people did not meet 
the ideal metric (Ford et al. 2012). The major risk factors other than the health behaviors included obesity, high 
blood cholesterol and other lipids, high blood pressure, DM, and metabolic syndrome (MetS); which also 
constitute the common comorbidities of CVD.  
 
Obesity is a  major risk factors for CVD, including CHD (Klein et al. 2004), stroke(Poirier et al. 2009), atrial 
fibrillation (AF)(Mi et al. 2016; Aune et al. 2017), venous thromboembolism (VTE)(Mi et al. 2016), and 
congestive heart failure (CHF)(Virani et al. 2020). According to a systematic analysis based on The Global 
Burden of Disease Study in 2017, obesity remained a key factor driving the leading causes of burden in high-
middle and middle SDI countries (e.g., ischemic heart disease, ischemic stroke, diabetes, low back and neck 
pain)(Kyu et al. 2018). For adults, BMI was categorized as overweight (25.0 ≤ BMI ≥ 29.9 kg/m2) and obese 
class I (BMI 30-35 kg/m2), class II (BMI >35-39.9 kg/m2), and class III (BMI ≥ 40 kg/m2) (National Heart, 
Lung, and Blood Institute). According to 2015-2016 data from NHANES, the prevalence of obesity among 
adults was 38.3% (36.0% of males and 40.4% of females), including 7.7% with class III (severe) obesity or a 
BMI≥ 40 kg/m2 (5.4% of males and 9.8% of females)(Hales et al. 2018). In a population-based longitudinal 
study, approximately half of the older adults (45-85 year of age) with metabolically healthy obesity (MHO) 
developed MetS and exhibited an increased risk for CVD compared to those with stable metabolically healthy 
obesity or healthy normal weight. The authors concluded that MHO is not a low-risk state for cardiovascular 
disease (Mongraw-Chaffin et al. 2018). This finding is  in line with a recent meta-analysis demonstrating that 
CVD risk was higher in MHO than metabolically healthy normal-weight participants (RR=1.45), but still lower 
than the individuals were metabolically unhealthy normal-weight (RR=2.07) and obese (RR=2.31) participants 
(Eckel et al. 2016). Investigators often define metabolically healthy obesity by the absence of MetS, the absence 
of insulin resistance (IR), or less often, the absence of abdominal adiposity or higher cardiorespiratory 
fitness(Stefan et al. 2013). A more strict criteria with simultaneous absence of high BP, dyslipidemia and 





Cholesterol is a primary risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). 
Hypercholesterolemia (high LDL-C) remained the fifth-leading risk factor for mortality from 1990 to 
2017(GBD Risk Factor Collaborators 2018). In adults, a total cholesterol (TC) of 200 to 239 mg/dL, measured 
by low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and triglycerides, is 
considered borderline high and  ≥ 240 mg/dL is considered high. According to an unpublished  NHANES data 
from 2013 to 2016 (National Center for Health Statistics 2017), among adults ≥ 20 years of age, the mean TC 
level was 190.08 mg/dL. The prevalence of TC ≥200 mg/dL was 38.2% including hypercholesterolemia 
(11.7%). Other lipid subfractions including LDL cholesterol (LDL-C) was 112.1 mg/dL on average among 
adults, and the age-adjusted prevalence of high LDL-C (≥ 130 mg/dL) was 29.4%. HDL cholesterol (HDL-C) 
was 54.2 mg/dL and the age-adjusted prevalence for HDL-C < 40 mg/dL was 28.5% in males and 8.9% in 
females. Lastly, the mean triglyceride was 95.6 mg/dL, and approximately 22.2% of adults had high triglyceride 
levels (≥ 150 mg/dL). Subclinical atherosclerosis (plaque or coronary artery calcification) was recognized 
among half (49.7%) of individuals without other cardiovascular risk factors and was associated with LDL-C at 
levels currently considered normal. A linear and significant increase was found in the prevalence of 
atherosclerosis from LDL-C 60-70 mg/dL category to the 150-160 category (from 11% to 64%) (Fernández-
Friera et al. 2017). Long-term exposure to elevated cholesterol levels (non-HDL-C ≥ 160 mg/dL) can lead to 
coronary artery disease (CAD) in later life with an adjusted HR, 1.39 per decade of hyperlipidemia (Navar-
Boggan et al. 2015). Particularly, among these makers, LDL-C is the dominant form of atherogenic cholesterol. 
Additionally, very low-density lipoprotein (VLDL) as the chief carrier of triglycerides  also proved to be 
significantly atherogenic(Grundy et al. 2019).  
 
High blood pressure (HBP) was ubiquitously recognized as the major risk factor for CVD and stroke 
(Chobanian 2003; Virani et al. 2020). The AHA has identified BP <120/<80 mmHg for adults as 1 of the 7 
components of ideal cardiovascular health. This represented for 55.1% in adults (20-49 years of age) and 19.9% 
of adults ≥50 years of age(Lloyd-Jones 2010). HBP was defined in the 2017 Hypertension Clinical Practice 
Guidelines as systolic blood pressure (SBP) ≥130 mmHg or diastolic blood pressure (DBP) ≥ 80 mmHg; or self 
-reported antihypertensive medicine use (Whelton et al. 2018). The prevalence of HBP among US adults was 
45.6% using 2017 guideline threshold; and the prevalence increased with age (26.1% vs. 59.2% vs 78.2 among 
those 20-44 vs. 45-64 vs. ≥65 years of age) (Virani et al. 2020). Male predominance was noted among adults up 




Statistics 2017). Genetic or family history has been associated with an increased risk of CVD and myocardial 
infarction (MI). Gene-environment interactions are considered important in the pathophysiology of hypertension 
(Cooper-DeHoff and Johnson 2016). The largest lifetime risk for CVD existed in angina, MI, and stroke. In a 
study of 1.25 million adults with hypertension.at age 60,  the prevalence was 60.2% for those with hypertension 
compared with 44.6% among those without hypertension. 
 
Diabetes mellitus (DM) is characterized by glucose dysregulation. It is diagnosed based on a fasting plasma 
glucose (FPG) ≥ 126 mg/dL, 2h post-challenge glucose ≥ 200 mg/dL during oral glucose tolerance test, random 
glucose ≥ 200 mg/dL with symptoms of hyperglycemia, or HbA1C ≥ 6.5%(American Diabetes Association 
2010). Type 2 DM, which accounts for 90-95% of DM, is a major risk factor for CVD, including CHD and 
stroke (Emerging Risk Factors Collaboration 2010). The prevalence of diagnosed DM was 10% among US 
adults based on the data from NHANES 2013 to 2016 (3.7% of undiagnosed DM and 37.6% of prediabetes) 
(National Center for Health Statistics 2017). Type 2 DM and insulin resistance was reportedly associated with 
increased risk for CVD mortality (Liu et al. 2016b). The altered glucose metabolism correlated strongly with 
diet,  contributed to obesity and type 2 DM (Joseph et al. 2017), and accounted for 90% of the burden of stroke 
(O'Donnell et al. 2016). 
The proposed mechanisms of the association is poorly understood, but may be related to  oxidative stress, low-
grade inflammation, and endothelial dysfunction subsequent to hyperglycemia (Matheus et al. 2013). More 
importantly, it could be explained by the multiple shared risk factors between DM and CVD, including 
hypertension, dyslipidemia, obesity, smoking, and lack of physical activity (Leon and Maddox 2015).  
 
Metabolic syndrome(MetS) is a multicomponent risk factor for CVD and type 2 DM reflecting a cluster of 
cardiometabolic risk factors related to abdominal obesity and insulin resistance(Virani et al. 2020). It is based on 
the presence of any 3 of the following 5 risk factors, including FPG ≥ 100 mg/dL, HDL-C <40 mg/dL, 
triglycerides ≥ 150 mf/dL,  SBP ≥ 130 mmHg or DBP ≥ 85 mmHg (or undergoing drug treatment for those 
conditions), and waist circumference >102 cm in males (>88 cm in females) (Alberti et al. 2009). The overall 
prevalence of MetS was 34.3% and increased with age (from 19.3% among 20-39 years of age to 54.9 among 
those ≥ 60 years of age(Shin et al. 2018). Obesity, parental history of DM, childhood MetS, BMI, and heart rate 
were risk factors for MetS(Virani et al. 2020). MetS was correlated with MI, stroke, CVD morbidity and all-





D. The relationship between CVD and chronic oral infection 
 
Chronic oral infections (dental caries, periodontal diseases including gingivitis and periodontitis) are among the 
most common chronic inflammatory diseases worldwide (Petersen et al. 2005). Periodontitis, being the sixth 
most common human disease, affects 11.2% of the world's population (Kaushal et al. 2019). Oral diseases 
(mainly periodontitis and caries) contributed the most to the "years lost to disability (YLD)" in age-standardized 
prevalence rates from 354 diseases globally (Forouzanfar et al. 2016). Growing evidence supports the 
independent association between severe periodontitis and several chronic non-communicable diseases (NCDs), 
including diabetes (Chapple et al. 2013; Sanz et al. 2018), cardiovascular disease (Tonetti and Van Dyke 2013; 
Sanz et al. 2020), chronic obstructive pulmonary disease (Linden et al. 2013), and chronic kidney 
disease(Sharma et al. 2016). Severe periodontitis appears to be a modifiable non-traditional risk factor for CVD, 
significantly associated with all-cause and cardiovascular mortality (Linden et al. 2012), particularly among the 
populations with multi-morbidity (Sharma et al. 2016; Liccardo et al. 2019). 
 
The term "cardiovascular disease" (CVD) was largely used as a general term for an atherosclerotic diseases, 
principally coronary heart disease, cerebrovascular disease and peripheral vascular disease. The Joint Consensus 
Report published by the World Heart Federation (WHF) and European Federation of Periodontology (EFP) in 
2019 (Sanz et al. 2020) examined the epidemiologic evidence on the association between periodontitis and CVD 
following the report of the joint workshop between EFP and the American Academy of Periodontology in 2013 
(Dietrich et al. 2013). The epidemiological evidence belongs to a variety of CVD categories: (1) subclinical 
cardiovascular disease (endothelial dysfunction, measured by mean carotid intima-media thickness) (de Boer et 
al. 2014) (2) coronary heart disease (myocardial infarction and other coronary events) (Renvert et al. 2010; Yu 
et al. 2015; Rydén et al. 2016; Herrera et al. 2020) (3) cerebrovascular disease or stroke (Sen et al. 2018; Aarabi 
et al. 2019) (4) peripheral artery disease (Ahn et al. 2016; Yang et al. 2018)(5) other CVD or conditions (heart 
failure, atrial fibrillation) (Chen et al. 2016) and (6) secondary(recurrent) cardiovascular events (Reichert et al. 
2016). To answer the first question: "Is periodontitis a risk factor/indicator for the CVD?", evidence mainly 
centers on coronary heart disease and cerebrovascular disease (Leira et al. 2017; Sanz et al. 2020). To answer 




periodontitis?" the consensus report concluded that there's currently limited evidence that CVD is a risk factor 
for the onset or progression of periodontitis (Sanz et al. 2020).  
 
The direct cause of CVD appears to be the rupture and thrombosis of atherosclerotic plaques resulting in blood 
flow inhibition and thus induction of CVD (Frostegård 2013). Atherosclerotic vascular disease is the leading 
cause of MI and cerebrovascular event and is now considered a chronic inflammatory disease (Libby et al. 
2009). Chronic inflammation plays a pivotal role in the initiation and progression of atherosclerosis and the 
immune response, involving multiple cell types, including macrophages, T-lymphocytes, mast cells, endothelial 
and smooth muscle cells (Conti and Shaik-Dasthagirisaeb 2015). Other than traditional risk factors, it has been 
hypothesized that various stimuli including chronic infection can trigger and sustain the state of heightened 
inflammation, eventually leading to the damage of vascular endothelium (Pothineni et al. 2017). Several 
biologically plausible mechanisms of the impact of periodontitis on CVD have been proposed over the past 
decades. Currently, the evidence has been centered on the translocated circulating oral microbiota directly or 
indirectly inducing systemic inflammation  impacting atherothrombogenesis (Dietrich et al. 2013). Periodontal 
bacteria have been identified distantly in atherosclerotic plaque (Kozarov et al. 2005; Ott et al. 2006; Fernandes 
et al. 2014; Figuero et al. 2014). In an animal model, infection with Porphyromonas gingivalis (P. gingivalis) 
increases atherosclerotic plaque volume with the accumulation of cholesterol esters and inflammatory mediators 
(Hayashi et al. 2011). Human serum IgA antibodies to P. gingivalis and other periodontal bacteria was found 
higher in patients with CVD and ischemic stroke than in controls (Pussinen et al. 2004; Hosomi et al. 2012; 
Aoyama et al. 2018). Secondly, periodontitis causes a local and systemic inflammatory response with increased 
counts of leukocytes, C-reactive protein (CRP), fibrinogen, cell adhesion molecules, and pro-inflammatory 
cytokines (Mustapha et al. 2007). Inflammatory response to the putative periodontal bacterial challenges 
(lipopolysaccharides) produce inflammatory mediators, including TNF-𝛼, prostaglandin, interleukin (IL) and 
proteolytic enzymes like matrix metalloproteinases (MMP), etc. (Herrera et al. 2020). In addition, dyslipidemia 
was found to be associated with periodontitis (Thapa and Wei 2016; Lee et al. 2018), and recent data suggests a 
synergistic effect of both periodontal bacteria and lipid-induced inflammation in the pathogenesis of CVD 
(Køllgaard et al. 2017). This might be explained by the increased reactive oxygen inducing structural 
modifications in circulating lipoproteins (Lönn et al. 2018) and altered gene-encoding cholesterol metabolism 





With the increased prevalence of dental implant therapy, chronic inflammation around dental implants is an 
emerging global burden among oral conditions. Peri-implant diseases are considered  biological complications 
around dental implants induced by the accumulation of bacterial biofilm (Lang et al. 2011; Sanz et al. 2012; 
Renvert et al. 2018). It includes peri-implant mucositis, soft tissue inflammation in the absence of bone loss 
(Heitz-Mayfield and Salvi 2018) and peri-implantitis, characterized by the inflammation within the peri-implant 
mucosa and progressive bone loss (Berglundh et al. 2018). The state of peri-implant health was defined as 
healthy peri-implant mucosa and alveolar bone without signs of inflammation (free of profuse bleeding upon 
probing or suppuration) (Araujo and Lindhe 2018). The prevalence was greatly influenced by the cut-off 
threshold of disease definition. In the past decade, a cut-off level of 2 mm was adopted in the majority of 
published literature (Sanz et al. 2012; Schwarz et al. 2018). The prevalence has been reported as 45% with a 
detectable bone loss > 0.5 mm on the patient level. If the cut-off threshold of bone loss was changed to ≥ 2 mm, 
which was defined as moderate to severe peri-implantitis, the prevalence was diagnosed as 14.5% (Derks et al. 
2016). Similar range of variability in prevalence on subject level (11.3% to 47.1%) was reported with different 
cut-off threshold from detectable (incipient) to bone loss > 3mm (Koldsland et al. 2010). In a systematic review, 
the prevalence of peri-implant mucositis and peri-implantitis were estimated ranging from 19% to 65% (mean 
43%) and from 1% to 47% (mean 22%) with a negative relationship with the threshold for bone loss (Derks and 
Tomasi 2015). The 2017 World Workshop defined peri-implantitis as progressive bone loss at 1-year following 
the delivery of the implant-supported prosthesis. In the absence of initial radiographs and peri-implant pocket 
depths (PPD), radiographic evidence of bone level ≥ 3 mm and/or PPD ≥ 6 mm in conjunction with profuse 
bleeding was required for the diagnosis of peri-implantitis (Renvert et al. 2018).  
 
Peri-implantitis occurs primarily as a result of an overwhelming bacteria insult and subsequent host immune 
response (Rosen et al. 2013). Peri-implant mucositis is assumed to precede peri-implantitis mirroring the 
progression of gingivitis to periodontitis (Jepsen et al. 2015). Inflammation of the peri-implant mucosa is 
dominated by plasma cells and lymphocytes (Sanz et al. 1991; Cornelini et al. 2001; Bullon et al. 2004) with  
larger inflammatory infiltrates with denser vascular structure outside the lesion (Carcuac and Berglundh 2014) 
and larger proportions of polymorphonuclear leukocytes (PMN) and macrophages (Berglundh et al. 2004). Peri-
implantitis has been shown to be a polymicrobial infection around dental implants and their related prosthetic 
components (Shibli et al. 2008; Persson et al. 2010; Hallström et al. 2012). Results from animal and human 




gingivalis, Prevotella intermedia (P. intermedia), Tannerella forsythia (T. forsythia), and Fusobacterium  
nucleatum (F. nucleatum) were found in both periodontitis and peri-implantitis (De Boever and De Boever 
2006; Heitz-Mayfield and Lang 2010; Mombelli and Décaillet 2011; Persson and Renvert 2014; de Waal et al. 
2017; Gürlek et al. 2017; Schwarz et al. 2018). Moreover, observational studies had linked peri-implantitis with 
opportunistic pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus (S. aureus) (Leonhardt et al. 
1999; Mombelli and Décaillet 2011), fungal organisms (Schwarz et al. 2015), and viruses (Jankovic et al. 2011). 
Compared to periodontitis, microbial communities of peri-implantitis were more complex and heterogenous 
(Padial-Molina et al. 2016; Rakic et al. 2016). Koyanagi and his colleagues used 16S rRNA sequencing to 
identify the phylogenetic tree of bacterial species in peri-implantitis and periodontitis. The microbial 
composition of peri-implantitis was more diverse than that of periodontitis. Fusobacterium spp. and 
Streptococcus spp. were predominant in both, while bacteria such as Parvimonas micra were only detected in 
sites with peri-implantitis (Koyanagi et al. 2013). Belibasakis et al. had identified that Spirochetes of the 
Treponema and Synergistetes cluster A are highly associated with peri-implantitis (Belibasakis et al. 2016). 
There were contradictory observations of opportunistic S. aureus in the peri-implant lesion. It once appeared to 
play a predominant role for the development of a peri-implantitis (Renvert et al. 2007; Renvert et al. 2008; Salvi 
et al. 2008; Zhuang et al. 2016), especially associated with suppurative implant sites (Leonhardt et al. 1999; 
Kronström et al. 2001; Albertini et al. 2015); Revert et al. found that after treatment of most severe peri-
implantitis, increasing levels of IL-1𝛽 and S. aureus (r2=0.9) were found only at implants in a  non-stable 
condition (Renvert et al. 2017). However, conflicting results had been reported (Canullo et al. 2015; de Waal et 
al. 2017). Nevertheless, S. aureus was consistently found to be a frequent isolate pathogen in the oral cavity, 
which has been seen as an important source in terms of cross-infection and dissemination to other body sites 
(McCormack et al. 2015). More importantly, Staphylococcus aureus bacteremia (SAB) was significantly 
associated with severe cardiovascular consequences, including chronic heart failure (Smit et al. 2016), infective 
endocarditis (Fowler et al. 2005; Salgado-Pabón et al. 2013; Baddour et al. 2015), pericardial infection after 
cardiac surgery (Chamis et al. 2001; Mozaffari et al. 2014), and cardiovascular implantable electronic device 
(CIED) infection(Sohail et al. 2015; Maskarinec et al. 2017). As a result, it has raised interest among medical 
and dental professionals. 
 
A cross-sectional study has proved a similar pattern of host response and bone destruction between peri-




periodontitis/ gingivitis sites compared to healthy implants.  (Gürlek et al. 2017). The immune response at peri-
implantitis sites was similarly high (or higher) compared to periodontitis and can also be observed among 
different individuals (Ata-Ali et al. 2015; Recker et al. 2015; Cionca et al. 2016). Recent systematic reviews 
demonstrated pro-inflammatory cytokines, mostly  IL-1𝛽 and TNF-𝛼 were significantly increased at mucositis 
and peri-implantitis sites (Faot et al. 2015; Duarte et al. 2016; Ghassib et al. 2019). Given the similarities of 
microbial profiles and the heightened immune response towards chronic inflammation, a potential link between 
peri-implantitis and CVD was proposed. A recent study has shown that patients with peri-implantitis had a high 
prevalence of moderate plaque and bleeding upon probing (BOP), and a significant co-morbidity occurred in 
individuals with cardiovascular diseases (27%). CVD was statistically significantly associated with the 
prevalence and concentration of P. intermedia in the peri-implantitis sulcus (Lachmann et al. 2013). In a 
retrospective study investigating the risk factors related to peri-implantitis, a history of CVD was found in 
27.3% of individuals with peri-implantitis, and the odds ratio (OR) of having peri-implantitis and a history of 
CVD was 8.7 (95% CI: 1.9, 40.3 p<0.006)(Renvert et al. 2014). It was also observed in a cross-sectional study 
that the heart disorder associated with peri-implantitis with a significant difference in prevalence (13.1% vs. 
6.9%, p=0.012)(Dalago et al. 2017). On the other hand,  systemic low-grade inflammation has been associated 
with coronary heart disease (Koenig 2018). The association could be attributed to an inflammatory marker such 
as C reactive protein or a bacteria potentially linked to the chronic infection, such as Chlamydia pneumoniae 
(Danesh et al. 2000), or chronic gastric infection with Helicobacter pylori(Danesh et al. 1997). Classic vascular 
risk factors (such as smoking, obesity, insulin resistance, and metabolic syndrome) were also considered(Lopez-
Candales et al. 2017). The inflammation associated with peri-implant mucositis and peri-implantitis and their 
potential to induce systemic low-grade inflammation has recently garnered attention in the research community 
(Golub and Lee 2020; Sorsa et al. 2020). The challenge of implant dentistry is no longer just placing a titanium 
implant in bone, patients receiving implants often presented with advanced age, function dependency, systemic 
comorbid conditions, and frailty. Naturally, aging leads to deterioration of the host defense towards bacterial 
challenges and adverse impact on healing capacity and peri-implant health (Ebersole et al. 2018; Schimmel et al. 
2018). It has been widely conceptualized that chronic antigenic stress may mount an inflammatory response 
which was associated with the pathogenesis of all age-related diseases. Thus, underlying local low-grade 
inflammatory activity around dental implants triggered by asymptomatic infection with bacterium, may lead to 




cholesterol (Bruunsgaard et al. 2003; Krabbe et al. 2004); particularly in the aging population or people with 
multiple comorbid diseases(Lopez-Candales et al. 2017). 
 
In contrast to the above, it was reported that patients with CVD, including ischemic heart disease, stroke, and 
hypertensive heart disease had similar high implant survival rates (98-100%) to patients without CVD (Heitz-
Mayfield et al. 2018). According to the 2017 World Workshop Consensus (Schwarz et al. 2018), the major risk 
indicators of developing peri-implantitis were a history of chronic periodontitis, poor plaque control, and lack of 
regular maintenance after implant therapy. The evidence implicating systemic conditions as risk factors for peri-
implant disease is inconclusive. Only limited evidence was present with respect to CVD or other systemic 
conditions(Schimmel et al. 2018; Schwarz et al. 2018). The current available epidemiological evidence with 
regards to the association between peri-implant disease/implant survival and CVD-related conditions was 
summarized in the Table 1. 
 
In the present study, it was hypothesized that chronic inflammation at sites of peri-implant disease may induce  
systemic low-grade inflammation and increase the risk of cardiovascular disease via a potential infectious axis 
between the two diseases similar to that between chronic periodontitis and CVD. The purpose of this case-
controlled design, cross-sectional study was to assess the relationship between peri-implantitis and CVD. The 
critical question is "does peri-implantitis impart an increased risk for future cardiovascular disease? ". Secondly, 
we compared the diagnostic value of  systemic and peri-implant protein biomarkers and peri-implant microbial 
profiles for peri-implantitis in CVD and non-CVD patients. The null hypothesis was that patients with peri-
implantitis are not at elevated risk for developing cardiovascular diseases (CVD). 
 
 
Chapter III. Material and Methods 
 
A. Study Design 
In order to investigate the relationship between peri-implantitis and CVD, a case-controlled design, cross-
sectional study was implemented based on a power calculation to satisfy the two-tailed confidence level of 95% 
and a power of 80% with a ratio of 2 to1 (Case to Control). Individuals without CVD were grouped as "Control', 




CVD diagnosis. It was assumed the percentage of "Controls" exposed to the peri-implantitis is 40%, according 
to Derks et al., which was diagnosed based on the similar case definition of this study (detectable bone loss). 
With a hypothetical prevalence 67% of "Cases", the sample size was calculated using an open-source OpenEpi 
statistic software version 3.01 with a total sample size of 137 composed of 91 subjects in the "Cases", and 46 
subjects in the "Control" group. This was in accordance with the a priori power calculation based on the 
comparison of pro-inflammatory biomarker interleukin-1𝛽 concentration among the two groups. It was assumed 
that IL-1𝛽 level in the "Cases" (CVD) group is 200±135 pg/ml, and the "Controls" (non-CVD) group is 
130±135 pg/ml (Offenbacher et al. 2009; Gürlek et al. 2017; Renvert et al. 2017), and a total sample size of 134 
(89 in the "Cases" group, and 45 in the "Controls" group with the allocation ratio of 2:1) was acquired to satisfy 
the 80% power at the 5% significance level. In order to test the hypothesis of this investigation, the time of peri-
implantitis onset was evaluated by  radiographic evidence. As a result, the subjects with peri-implantitis being 
observed after the diagnosis of CVD being diagnosed were excluded in this case-control study. 
 
B. Study population 
This study, conducted from April 2018 to June 2020, was approved by the Institutional Review Boards of the 
University of Michigan Medical School (Study ID: HUM00130676) and at the Department of Periodontics and 
Oral Medicine, School of Dentistry, University of Michigan in collaboration with the Frankel Cardiovascular 
Center, Michigan Medicine. Participants enrolled in the "Cases" CVD group were those with an established 
diagnosis of cardiovascular diseases (CVD) or atherosclerotic cardiovascular disease (ASCVD) including 
coronary heart disease, cerebrovascular disease, and peripheral artery disease after at least one dental implant 
placement; and those who had received interventions to prevent a subsequent CVD event or with a history of a 
cardiovascular event (myocardial infarction, stroke, stable or unstable angina, transient ischemic attack, or 
coronary or other arterial revascularization including coronary artery bypass graft or coronary transluminal 
angioplasty with or without a stent) after at least one dental implant placement and functioning for at least 6 
months. The diagnosis of CVD was assigned by an internist or a cardiologist by the findings of symptoms, 
ischemic changes in ECG, findings in coronary angiography, and a history of a previous CVD event. All 
patients with the diagnosis of CVD were recruited by the screening process from the database of electronic 
health records from the Frankel Cardiovascular Center, Michigan Medicine and the School of Dentistry, 
University of Michigan. The "Controls" non-CVD group were patients with at least one non-mobile dental 




process via electronic health records in the School of Dentistry, University of Michigan. Eligibility of inclusion 




1. Adult subject age ≥ 25 years old 
2. All subjects must have at least one implant non-mobile, in function for at least 6 months 
3. For the "Cases" (CVD) group (i) who had established diagnosis of cardiovascular disease (CVD) or 
atherosclerotic cardiovascular disease (ASCVD) including coronary heart disease, cerebrovascular 
disease, and peripheral artery disease  after at least one dental implant placement (ii) who had received 
interventions to prevent a subsequent CVD event or with a history of a cardiovascular event 
(myocardial infarction, stroke, stable or unstable angina, transient ischemic attack, or coronary or other 
arterial revascularization) after at least one dental implant placement  
4. No known episode of peri-implant infection (mucositis/peri-implantitis) within the past year 
5. No known mechanical complication affecting the implant restorations within the past year 
 
Exclusion Criteria 
1. Unable to comply with the study protocol  
2. Head/neck radiotherapy, chemotherapy, or immunosuppressed therapy in the past 6 
months 
3. Pregnant or lactating female 
4. > 2 weeks use of antibiotics in the past three months 
5. Patients taking medications known to modify bone metabolism (e.g., IV 
bisphosphonates or oral bisphosphonates for more than 4 years, long-term use of 
corticosteroids, long-term use of hormone replacement therapy) 
6. Drug addiction or intoxication other than habitual tobacco consumption 





C. Clinical and radiographic assessment 
The updated medical history was interviewed by constructed questionnaire and documented in the case report 
form. Medical history was collected including age, gender, ethnicity, height, weight, BMI, health history 
including diabetes mellitus (DM) and glycemic control, hypertension (systolic pressure >130 or diastolic 
pressure > 80 mmHg measured on various occasions or taking antihypertensive medications), dyslipidemia or 
metabolic disease, osteoporosis, rheumatoid arthritis or other major diseases), and life-style (smoking including 
data of dose/year and alcohol consumption including data of frequency/units). The medication list and the 
family medical history with regard to heart attack, stroke, cancer, diabetes, hypertension, etc. were also 
recorded. Physical assessments were performed including vital signs check (pulse and blood pressure), fasting 
plasma glucose test, extra-oral exam (communication, general physical status, face and muscle tone, thyroid, 
lymph nodes palpation) and intra-oral exam (color, contour, and texture of soft tissue, hard palate, tonsils, 
tongue, and mouth floor and general dental and occlusion exam). 
 
Dental history was documented including the history of periodontal maintenance and the time of implant 
insertion, implant location, and potential history of treating peri-implantitis. All the implants were assessed by 
radiographic examination first to identify the "most bone loss implant" and verify the eligibility if the time of 
the placement of selected implant was prior to the time when the diagnosis of CVD was established by 
searching the electronic dental record in the University of Michigan or acquiring from the patient's dental record 
if possible.  
 
Standardized long cone paralleling periapical digital radiographs of all the implants were taken if radiographs in 
the electronic dental record were taken longer than one-year previously or had significant changes in the pocket 
depth and tissue status since the last dental examination within one-year. Similarly, in the remaining natural 
teeth, multiple peri-apical radiographs were obtained if there were no recent radiographs within two years, or 
were updated in the periodontal susceptible patients if radiographs were taken more than one-year previously. 
The radiographic examination was performed using a paralleling long-cone technique with Rinn-type film 
holder (XCP-DS® Sensor Holder, Dentsply Sirona) and examined under an in-house computer software 
(MiPACS Dental Enterprise Viewer) to discern the bone loss apical to the most coronal portion of the 
intraosseous part of the implant (or anticipated level after initial bone remodeling) measured in millimeters to 




implants) were determined based on the macro-design shown on the radiographs or acquired from the dental 
records in the dental school. If the implant system could not be identified, they were excluded from the stratified 
statistics on the implant surface category. All assessments were made by one self-calibrated examiner under the 
same viewing conditions.  
 
Prior to the clinical assessment, collection of plaque samples and peri-implant crevicular fluid (PICF) around the 
targeted "diseased" or "healthy" implant and the gingival crevicular fluid (GCF) samples around the most-
diseased or healthy natural tooth were completed to avoid the contamination of the PICF/GCF samples after the 
assessment of bleed upon periodontal probing. The process of sample collection was detailed in the section D. 
Serum, subgingival plaque and PICF/GCF sample collection  
 
Clinical assessments were recorded at 6 sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-
lingual, and disto-lingual) around the "most radiographic bone loss" implants. If the patient had received more 
than one implant, clinical data and PICF/plaque samples were collected only from the most bone loss peri-
implantitis-affected implant. The clinical data collected included pocket depth (PD), clinical attachment level 
(CAL) with the reference of implant crown margin, modified plaque index (0, 1, 2, 3) (modPI) (Mombelli et al. 
1987), modified gingival index (0, 1, 2, 3)(modGI) (Mombelli et al. 1987), BOP (+/-), and suppuration (+/-). 
Keratinized mucosa widths (KMW) were measured at buccal/lingual surface.  Finally, the implant restoration 
type (fixed, removable, or hybrid), connection type (cement or screw-retained), stand-alone prosthesis or 
splinted, mobility (+/−), and the opposing arch (natural tooth or implant-supported prosthesis) were 
documented. All the clinical measurements were completed using a UNC-15 periodontal probe (Hu-Friedy, 
Chicago, IL, USA). Clinical photographs were acquired when possible. Clinical assessment further included a 
full-mouth periodontal chart to record PD, CAL, BOP (+/-), keratinized mucosa width (KMW), furcation 
involvement (grade 1, 2, 3) (Hamp et al. 1975), mobility, and occlusal evaluation (including any signs of 
parafunctional activities). Peri-implant status and overall periodontal status obtained from the clinical data were 
determined by the case definitions in accordance with the 2017 World Workshop (see E. Case definition of peri-
implantitis and periodontitis) and stratified into subgroups for further statistical analysis.  
 
 





Arterial blood samples were collected in BD Vacutainer® Serum 10 mL tubes (Becton Dickson and Company; 
Franklin lakes, NJ, USA) following the standard procedures suggested by the manufacturers from fasting 
patients (at least 8h). Whole blood samples were allowed undisturbed at room temperature for 30 mins post-
collection, followed by tube centrifugation at 2700 rpm for 15 mins. Serum samples (approximately 1 milliliter) 
were immediately (within 30 mins) aliquoted into a labeled Eppendorf® polypropylene cryovial using pipette 
technique (multiple cryovials were obtained based on the volume of the blood draw) and placed into a cold box 
for transporting to the lab and stored at -80℃ freezer until the analysis.  
 
Peri-implant crevicular fluid (PICF) 
The PICF samples were collected from the "most radiographic bone loss" implant per patient, either from the 
mesio-buccal aspect of the healthy implant site or the deepest implant pocket of the "most radiographic bone 
loss implant".  Each implant crown was dried with sterile gauze, isolated using cotton rolls and dried with gentle 
air spray. The supra-gingival plaque was removed using a sterile currete avoiding damage to the soft tissues. 
PICF samples were collected using methylcellulose strips PerioPaper® (Oraflow Inc., Smithtown, NY, USA) 
gently placed into the cleansed and dried pocket for 1 min. PerioPaer®  strips contaminated with blood were 
discarded and the site was re-sampled after 90s.The samples were transferred into labeled Eppendorf® 
polypropylene cryovials, and stored in a -80℃ freezer for further analysis.  
 
Plaque biofilm  
Subgingival plaque biofilms were collected at the same implant site after the PICF collection to establish the 
relationship between biomarker and microbial profiles. Sterile paper points (size 25 taper Absorbent Points, 
Dentsply Sinora) were inserted apically into the peri-implant sulcus until meeting resistance. They were kept at 
the base of the sulcus/pockets for 30 seconds. The samples were immediately placed into labeled vials 
containing 500 µl of stabilizing buffer (RNAprotect™, Ambion, Austin, TX, USA) to prevent mRNA 
degradation during transportation. They were hand-shaken for 10s, then vortexed for 30s, and stored in a -80℃ 
freezer until analysis.  
 




GCF samples were taken from 2 chosen sites from each patient. Based on the previous periodontal record and 
radiographic examination, one was collected from the most severe periodontitis site (deepest PD) in the subjects 
with chronic periodontitis and the other one was collected from a healthy site (mesio-buccal site of healthy 
tooth). Two healthy or gingivitis sites were randomly chosen in the subjects with healthy periodontal status. 
Prior to  collection, supragingival plaque was removed using a sterile instrument. The sites were isolated using 
cotton rolls and dried using a short blast of air (not into the sulcus/pocket). GCF samples were collected using 
methylcellulose strips PerioPaper® (Oraflow Inc., Smithtown, NY, USA) gently placed and kept in the dried 
pockets for 30 seconds. PerioPaper® strips contaminated with blood were discarded and re-sampled after 90 s. 
Subsequently, GCF strips were stored in cryovials at -80°C until extraction for analysis.  
 
E. Case definition of peri-implantitis and periodontitis 
(1) The case definition of peri-implant health and peri-implant disease including peri-implant mucositis and 
peri-implantitis implemented in the current investigation followed the diagnostic criteria proposed in the 
consensus report of 2017 World Workshop (Berglundh et al. 2018; Renvert et al. 2018).  
• Peri-implant health: (1) absence of peri-implant signs of soft tissue inflammation (redness, swelling, 
profuse bleeding on probing (BOP) (2) no increase in probing depth compared to previous examination (3) 
absence of further bone loss beyond crestal bone level changes resulting from initial bone remodeling 
• Peri-implant mucositis (MU): (1) presence of peri-implant signs of inflammation (redness, swelling, line or 
drop of bleeding within 30 seconds following probing (2) absence of further bone loss beyond crestal bone 
level changes resulting from initial bone remodeling 
• Peri-implantitis (PI): (1) presence of peri-implant inflammation (2) increasing probing depth (PD) 
compared to previous examinations (3) radiographic evidence of bone loss beyond crestal bone level 
changes resulting from initial bone remodeling. In the absence of previous radiographs, radiographic bone 
level ≥ 3 mm (apical of the most coronal protion of the intraosseous part of the implant) in combination 
with BOP and PD ≥ 6 mm.   
In order to discern the inflammatory burden of peri-implantitis, another cut-off threshold of peri-implantitis 
(BOP/suppuration and radiographic bone loss ≥2mm) was implemented in the analysis, (moderate to severe 
peri-implantitis) (Sanz et al. 2012; Derks et al. 2016). Further severity of peri-implant bone loss was 
analyzed statistically, including mild peri-implantitis (bone loss< 2 mm), moderate peri-implantitis (bone 




• Peri-implant disease (PID) was defined as chronic inflammation around dental implant, including peri-
implant mucositis and peri-implantitis. 
 
(2) The case definition and severity classification of periodontal health and periodontitis implemented in current 
investigation  followed the diagnostic criteria proposed in the consensus report of 2017 World 
Workshop(Chapple et al. 2018; Lang and Bartold 2018; Papapanou et al. 2018; Tonetti et al. 2018). 
 
Case definition 
• Periodontal health: absence of clinical detectable inflammation, which including intact periodontium and a 
reduced periodontium presented with stability or disease remission after treatment   
• Periodontitis: (1) ≥ 2 non-adjacent teeth presented with interdental CAL (2) Buccal CAL ≥ 3 mm with PD ≥ 
3 mm detectable at ≥ 2 teeth (excluded conditions such as gingiva recession, caries, vertical fracture, etc.) 
The purpose of stratified analysis of the classification (severity) of periodontal health and disease in the current 
investigation was to evaluate the impact of periodontitis disease severity of the remaining teeth onto the 
systemic inflammation burden accompanying with the peri-implant disease. If only one area (adjacent teeth) 
presented with interdental CAL, or teeth with periodontal stability/remission, the case was categorized as 
"periodontal healthy". 
 
Classification of periodontitis  
Staging: based on severity defined by the level of interdental CAL, radiographic bone loss (RBL) and tooth loss 
due to periodontitis, in combination with complexity to classify 4 stages of chronic periodontitis.  
• Stage I: initial periodontitis  
• Stage II: moderate periodontitis 
• Stage III: severe periodontitis 
• Stage IV: advanced periodontitis 
 
Greatest CAL 
RBL Toth loss Complexity 
Stage 1 1-2 mm Coronal third 
<15% 
No Maximum PD ≤ 4 mm 
Mostly horizontal bone loss 
Stage II 3-4 mm Coronal third 
<15% 
No Maximum PD ≤ 5 mm 




Stage III ≥ 5 mm Extending to mid-
third and beyond 
≤ 4 teeth 
PD ≥ 6 mm 
Vertical bone loss ≥ 3 mm 
Furcation involvement Class II or III 
Stage IV ≥ 5 mm Extending to mid-
third and beyond 
≥ 5 teeth 
< 20 remaining teeth (10 opposing pairs) 
Need for complex rehabilitation due to 
masticatory dysfunction 
 
Grading: based on the indirect evidence of disease progression including % bone loss/age and case phenotype 
(consistency of destruction and biofilm deposits) and two risk factors (smoking and diabetes). Additionally, the 
risk of systemic impact of periodontitis also was taken into consideration by the measurement of high-sensitivity 
C-reactive protein (hsCRP). (the direct evidence was not available in all samples) 
• Grade A: slow rate of progression 
• Grade B: moderate rate of progression 
• Grade C: rapid rate of progression 
 % bone 
loss/age 
Case phenotype Smoking Diabetes hsCRP 





< 1 mg/L 




< 10 cigarettes/day 
HbA1c < 7.0% in 
diabetic patients 
1-3 mg/L 




≥ 10 cigarettes/day 
HbA1c ≥ 7.0% in 
diabetic patients 




F. Laboratory analysis 
Serum Analysis 
High-sensitivity C-reactive protein (hsCRP) was measured in the serum samples using RayBio® Human CRP 
ELISA assay (RayBiotech, Inc., Norcross, GA, USA). Optical density was measured at 450 nm, and the 
concentration was determined by interpolation from a calibration curve of known concentrations with a dilution 
factor of 1000X. The second part of serum samples were analyzed using human custom Quantibody® 
(multiplexed sandwich ELISA-based) Arrays (RayBiotech, Inc., Norcross, GA, USA) to detect and quantify the 
cytokine levels including interleukin-1 beta (IL-1𝛽), interleukin-6 (IL-6), plasma tumor necrosis factor-alpha 




protocol. After the capture of antibodies and  incubation, the target cytokine is trapped and arrayed on the glass 
plates. By addition of the streptavidin-conjugated Cy3 equivalent dye, the laser scanning and multiplex 
detection was completed. Separately, fibrinogen was measured using Human Fibrinogen SimpleStep ELISA® 
kit (Abcam, Cambridge, UK) via high-sensitivity RabMab® antibodies to detect the lower amounts of fibrinogen 
in the serum samples. The assay was performed according to the manufacturer’s instructions. Optical density 
was measured at 450 nm using an EZ Read 400 Microplate Reader (Biochrom, Holliston, MA, USA). Finally, 
the remaining serum samples were analyzed after a 1:5dilution  with isotonic saline with the chemistry 
automated analyzer and regent kits (ADVIA® 1800 Chemistry System, Siemens Healthcare Diagnostics Inc., IL, 
USA) for the lipid panel including total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), and triglycerides. The total cholesterol/HDL, LDL/HDL ratio was 
automatically calculated.  
 
PICF/GCF Analysis 
A 20 µl extraction solution containing 10g/ml aprotinin, 1mM phenylmethylsulfonyl fluoride, and 0.1% human 
serum albumin in phosphate-buffered saline (PBS, pH 7.4) was pipetted directly onto the cellulose portion of 
each PerioPaper® strip and secured at the top of a 12*75 mm polystyrene culture tube using a cap to hold it in 
place. After centrifugation at 2000 rpm at 4°C for 5 min, each strip was washed five times to yield a total elution 
volume of 100 µl. The samples were stored at -80°C until the antibody array quantification. The samples were 
thawed and quantitative assessments of biomarker expression in PICF and GCF samples were performed using 
custom human Quantibody® Arrays (RayBiotech, Inc., Norcross, GA, USA). Targeted biomarkers included 11 
kinds: hsCRP; pro-inflammatory and angiogenic biomarkers including interleukin-1 beta (IL-1 𝛽), interleukin-6 
(IL-6), plasma tumor necrosis factor-alpha (TNF-𝛼), vascular endothelial growth factor (VEGF); T-cell 
modulator: interleukin-17 ( IL-17); chemokine: interleukin-8 (IL-8); inflammation mediator and proteolytic 
enzymes: matrix metallo-proteinase-8 (MMP-8), and biomarker for bone metabolism: osteoprotegerin (OPG) 
and tissue inhibitor of metalloproteinase-2 (TIMP-2), and myeloperoxidase (MPO). Prostaglandin E2 (PGE2) 
was separately analyzed by the ELISA assay as described above. The validity of the standard curve for each 
protein was confirmed by visual inspection and managed the outliners lower than the limit of detection (LOD) 
as the lowest value as LOD.   
 




Plaque samples absorbed onto paper points were sent out for a commercial laboratory (Zymo Research, Irvine, 
CA) to process and analyze by 16S rRNA next-generation sequencing (NGS) technique (ZymoBIOMICS® 
Targeted Metagenomic Sequencing Service). The mock microbial composition of the ZymoBIOMICS® 
microbial community positive standard measured in this project was demonstrated in Supplemental Figure 1. 
Blank extraction samples were used as negative controls. The total DNA extraction was completed by 
ZymoBIOMICS®-96 MagBead DNA Kit. The 2 µl per sample out of 50 µl DNA extract were prepared for 
targeted sequencing with the Quick-16S™ NGS Library Prep Kit in real-time PCR machines to control cycles 
and limit PCR chimera formation. With the Quick-16S™ primer sets V3-V4, the final library was sequenced on 
Illumina® MiSeq™ with a v3 reagent kit (600 cycles). Unique amplicon sequences were inferred from raw reads 
using the Dada2 pipeline (Callahan et al. 2016). Next, the taxonomy was assigned with the Zymo Research 
Database as a reference. Composition visualization, alpha-diversity (OTU diversity within sample using 
observed species), and beta-diversity (OTU diversity among sample communities) analyses were performed. 
The abundance among different groups were identified by linear discriminant analysis (LDA) effect size 
algorithm (LEfSe) (Segata et al. 2011). The "Absolute Abundance Quantification" was made possible by 
calculating the number of gene copies per microliter in each DNA samples using an equation generated by the 
plasmid DNA standard curve. The composition (%) of the total sample was calculated to evaluate the patterns of 
clusters of microbial distribution among samples, and represented in the taxonomy heatmaps. The genomic 
DNA was stored at 4℃   until next step of quantitative real-time PCR to analyze the targeted species shown to 
be abundant in the 16S NGS analysis. In addition, the interested species Staphylococcus aureus (Sau31 gene) 
was also targeted. Real-time quantitative polymerase chain reaction (RT-qPCR) were performed by a 
commercial laboratory (Microgen Diagnostics, Texas, USA) on the LightCycler 480 II running Lightcycler 480 
software (Roche Molecular System, Inc.). Proprietary lab-developed probe-based assays were performed using a 
Ct cutoff of 35 cycles limiting off-target amplification detection and primer dimers with custom primers. The 
bacterial load was determined using standard curves of qPCR targets with known copy numbers and absolute 
copies were calculated from sample volume. 
 
G. Data Analysis  
Patient-reported or physician-reported diagnosis of cardiovascular disease (CVD) was reported by 8 categories: 
(1) Coronary heart disease (CHD) including myocardial infarction (MI), angina pectoris, congestive heart 




disease (PAD) (4) rhythm disorders (pacemaker implant) (5) valvular disease (6) subclinical atherosclerosis (7) 
aortic disease including thoracic or abdominal aortic aneurysm and (8) Cardiomyopathy and heart failure, 
venous disease, etc. For subgroup analysis, age was divided into 5 age categories of every 10-years of interval. 
To assess potential confounders, selected confounding factors in the structured questionnaires included: 
demographic factors (age, gender), cardiovascular risk factors (hypertension, diabetes mellitus (DM), high 
cholesterol, overweight and obesity (BMI), familial cardiovascular risk factors (hypertension history, DM 
history, and CVD history), behaviors (smoking and alcohol drinking).  
Among them, DM, hypertension, and high cholesterol were also confirmed by the use of medications for each 
specific disease. Smoking was categorized into three subgroups including current-, ex-, and never-smoker. The 
years of quitting smoking in ex-smokers were divided into 4 types (within 5 years, 5-10 years, 10-15 years, and 
>15 years) (Table 2).  Alcohol consumption was further categorized into dose-dependent 4 subgroups based on 
the risk threshold for the CVD (100g per week, which was equivalent to 7.1 units in US ) (Wood et al. 2018) 
including social drinker, < 7 units/week, 7-14 units/week, and >14 units/week. Body mass index (BMI) was 
computed by dividing the weight in kilograms by the square of height in meters, and categorized into 
underweight (BMI< 18.5), normal weight (BMI: 18.5-24.9), overweight (BMI: 25-29.9), obesity (BMI: 30-
39.9); and the obesity was further subdivided into class I (BMI 30 to <35), class II (BMI 35 to <40), and class 
III: severe obesity (BMI> 40)(World Health Organization 1997). Fasting glucose level was categorized into 4 
types according to the corresponding HbA1C level to reflect  glycemic control, including < 100 mg/dl (normal), 
100-125 mg/dl (prediabetes), 126-153 mg/dl (well-controlled DM), and 154-183 mg/dl (moderate-controlled 
DM), and > 183 mg/dl (poor-controlled DM). Metabolic syndrome was determined when any 3 of the following 
5 risk factors were met (Grundy et al. 2004): (1) fasting glucose ≥ 100 mg/dL or undergoing drug treatment for 
elevated glucose (2) HDL < 40 mg/dL in males or < 50 mg/dL in females or undergoing drug treatment for 
reduced HDL-C (3) Triglycerides ≥ 150 mg/dL or undergoing drug treatment for elevated triglycerides (4) BMI 
higher than BMI ≥ 25 (Overweight) which is equivalent to waist circumference (WC)> 102 cm in males or WC 
>88cm in females (5) systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or 
undergoing drug treatment for hypertension in a patient with a history of hypertension. Dyslipidemia from the 
lipid panel analysis was diagnosed based on the following standards(Grundy et al. 2019): (1) total cholesterol (< 
200 mg/dL= normal, 200-239 mg/dL= borderline high, ≥ 240 mg/dL= high) (2) low-density lipoprotein 
cholesterol (LDL-C) [< 100 mg/dL= optimal, 100-129 mg/dL= above optimal, 130-159 mg/dL= borderline 




high-density lipoprotein cholesterol (HDL-C) (< 40 mg/dL= low (suboptimal) in men (< 50 mg/dL in women), 
40-60 mg/dL= borderline in men (50-60 mg/dL in women), and  >60 mg/dL= high (optimal) (4) triglycerides [< 
150 mg/dL= normal, 150-199 mg/dL= borderline high, 200-499 mg/dL= high (hypertriglyceridemia was 
defined as 150-499 mg/dL), >500 mg/dL= very high (severe hypertriglyceridemia)]. Furthermore, the ratio of 
total cholesterol/HDL was considered normal as < 4.5 in men or < 4.0 in women, and risk threshold for heart 
disease and stroke was > 5.0 in men and > 4.5 in women; and the ratio of LDL/HDL was normal as < 3.0 in men 
or < 2.5 in women, and risk threshold was > 3.5 in men and > 3.0 in women. Lastly, very-low-density 
lipoprotein cholesterol (VLDL-C) was estimated by one fifth of the triglycerides level, and an elevated VLDL-C 
level (≥ 30 mg/dL) is assessed as another important risk factor for CHD. A further step of analysis was executed 
to explore the 10-year risk index for ASCVD using the algorithm developed by American College of 
Cardiology(Lloyd-Jones et al. 2019). The determinants included age, gender, race, SBP, total cholesterol, HDL-
C, history of DM, smoking habits, and if patient was on hypertension treatment; and the 10-year ASCVD risk 
can be categorized as low-risk(<5%), borderline risk(5% to 7.4%), intermediate (7.5% to 19.9%), and high (≥ 
20%). Lastly, cardiometabolic disease was classified into 4 stages(Guo et al. 2014) 
Stage 1: Have one or two of the following risk factors: 
a. high waist circumference (≥112 cm in men, ≥88 cm in women) 
b. elevated blood pressure (systolic≥130 mmHg and/or diastolic =85 mmHg) or on anti-hypertensive 
medication 
c. reduced serum HDL cholesterol (<1.0 mmol/L or 40 mg/dL in men; <1.3 mmol/L or 50 mg/dL in 
women) or on medication 
d. elevated fasting serum triglycerides (≥1.7 mmol/L or 150 mg/dL) or on medication 
Stage 2 (Metabolic Syndrome or Prediabetes): Have only one of the following three conditions in isolation 
a. Metabolic Syndrome based on three or more of four risk factors: high waist circumference, elevated 
blood pressure, reduced HDL-c, and elevated triglycerides 
b. Impaired Fasting Glucose (IFG; fasting glucose ≥5.6 mmol/L or100 mg/dL) 
c. Impaired Glucose Tolerance (IGT; 2-hour glucose ≥7.8 mmol/L or140 mg/dL) 
Stage 3 (Metabolic Syndrome+ Prediabetes): Have any two of the following three conditions: 
a. Metabolic Syndrome 
b. IFG 
c. IGT 
Stage 4 (T2DM and/or CVD): Have Type 2 DM (T2DM) and/or CVD: 
a. T2DM (fasting glucose ≥126 mg/dL or 2-hour glucose ≥200 mg/dL or on anti-diabetic therapy) 
b. active CVD (angina pectoris, or status post a CVD event such as acute coronary artery syndrome, 
stent placement, coronary artery bypass, thrombotic stroke, non-traumatic amputation due to 
peripheral vascular disease) 
 
The periodontal status was evaluated in two ways. First, the presence of periodontitis was dichotomized into 
negative or positive periodontitis by the case-definition of 2017 World Workshop which was the presence of ≥ 2 
teeth with interdental CAL. Second, subjects were categorized into 4 periodontitis groups based on the 
classification of "Staging": stage 1 to stage 4. Lastly, periodontitis-associated covariates were categorized by the 




or more than once every 6 months, and the number of missing teeth was categorized into three ordinal scales 
including low (0-4), medium (5-9). and high (≥10 teeth). 
 
H. Statistical analysis 
Established diagnosis of CVD ("Cases") was the outcome variable in dichotomous format. The presence of peri-
implant disease was the main exposure variable. All the "Cases" and "Controls" were characterized as frequency 
(n) and percentage (%). A binominal logistic regression was performed to compare the two groups. A 
descriptive analysis of quantitative variables was reported in the measures of central tendency (mean, median) 
and dispersion (standard deviation, interquartile range); the bivariate analysis with a normal distribution was 
performed using Student's t test or ANOVA. Continuous parameters were tested using Mann-Witney test or 
Krunskal-Wallis H test to compare groups if the p-value was <0.05 in the Shapiiro-Wilk test.  
 
Median values were chosen as cut-off points to categorize dichotomized variates; then the crosstab analysis was 
implemented to analyze  sensitivity and specificity for the disease prediction. Multivariate logistic regression 
was used to evaluate the adjusted odds ratio (ORs) of the association between peri-implantitis and CVD.  
 
For fitting into the final model, first demographic variables were entered, Next, the systemic health and oral 
health-related variables were entered hierarchically. By comparing the explanatory power of model (fitness of 
evaluated by a change of -2 log likelihood) and the significance level < 0.05, variables contributing to the 
change of association were retained in the final logistic regression model. Additional subgroup analyses were 
performed to evaluate the impact of individual risk factors modifying the association. Subgroups included age, 
gender, smoking, alcohol, hypertension, DM, BMI, lipid profile were analyzed. Significance level was defined 
as P<0.05 and the statistical analysis was completed by the SPSS 24.0 statistical software package for MAC 
(IBM, Amorak, NY, USA). 
 
 
Chapter IV. Results 
 





A. Clinical parameters  
A total of 132 patients met the inclusion criteria of implant placement prior to the time of CVD diagnosis. After 
examining the radiographic evidence of progressive bone loss to discern the peri-implantitis status, 4 subjects in 
the CVD group were excluded from  statistical analysis since the time of peri-implantitis occurrence was not 
clear relative to the time of CVD diagnosis (diagnosis of CVD and the time of implant placement were within 2 
years). In other words, no radiographic before the time of the diagnosis of CVD was available to detect the bone 
loss after restoration. As a result, a "Case" group (CVD group) comprised of 82 participants and a "Control" 
group (non-CVD group) with 46 participants were included in the final statistical analysis.  
 
Demographic variables were demonstrated in Table 2, including the chi-square test to describe the strength of 
relationship and the univariate logistic regression for further step-wise prediction modeling. The majority of the 
diagnosis of cardiovascular disease in the CVD group was coronary heart disease (29.3%), followed by  
arrhythmias (28%), cerebrovascular disease (14.6%), and peripheral artery disease (14.6%). Among the patients 
with arrhythmia, half of the participants received pacemakers (14.6% in total CVD group) (Table 3).  
 
Mean value of age among the CVD group was significantly higher than the control group (75.0 ± 8.3 vs 69.3 ± 
10.1, p<0.01). The significance was also observed among different categories of age (Table 2). Gender was not 
shown to be significantly different between the two groups, however the majority of CVD group was composed 
of males with a ratio of 2 to 1. Smoking history was significantly different between the two groups. Although 
the percentage of current smokers was similar between two groups, the percentage of ex-smoker was 
significantly higher in CVD group (57.3%) compared to the non-CVD group (34.8%) (p= 0.03). Among the ex-
smokers, the composition of different years of smoking cessation was similar between two groups, and the 
majority of individuals in this group quit smoking more than 15 years previously (p= 0.52). Alcohol 
consumption was similar between the two groups. Family history of heart attack was reported in 58.5% patients 
in the CVD group which was significantly higher than the 30.4% in the control group (P=0.01). Family history 
of stroke, hypertension, diabetes, and cancer didn't show significant differences favoring the CVD group. With 
regard to the cardiovascular risk factors, CVD cases exhibited a significantly higher prevalence of hypertension 
than controls (59.8% vs 39.1%, p=0.03), whereas there was no significant difference in other variates including 
BMI, metabolic syndrome, diabetes, self-reported cholesterol, osteoporosis, and rheumatoid arthritis(RA) (Table 




accordance to the general trend of fasting glucose level and the lipid profile shown in the Table 4. Self-reported 
high cholesterol was found in the CVD group (46.3% vs 34.8%). There was a higher percentage of participants 
in the CVD group exhibiting low (suboptimal) HDL-C level (34.3%) compared to the control group (13.5%) 
(p=0.07). Interestingly, there was higher percentage of participants in the healthy group (51%) with above 
normal LDL-C levels compared to 22% in CVD group(p<0.01). This may be explained by the prevalent 
consumption of anti-dyslipidemia (statin) medications in the CVD group (60% in CVD versus 28% in non-CVD 
group). Most importantly, the 10-year ASCVD risk assessment was shown to be significantly higher in the CVD 
group at 68.7% compared to the control group (32.4%). Participants in CVD group were uniformly stage 4 of 
cardiometabolic disease. However, it was noteworthy that one third of the non-CVD group  presented with stage 
3 cardiometabolic disease, which was related to the lipid profile. Lastly, participants in CVD group exhibited a 
much higher percentage of multiple co-morbidities compared to the healthy group. One-third had at least one 
co-morbid factors, one-fifth had two co-morbid factors and one-third had 3 or more  co-morbid factors. The 
most common co-morbid factor was  metabolic disease, followed by obesity, diabetes, depression, osteoarthritis, 
and cancer.  
 
Prevalence of Peri-implantitis 
The prevalence of peri-implant health defined by the absence of signs of soft tissue inflammation (lack of BOP) 
and marginal bone loss beyond the initial physiologic bone remodeling was found in 9.8% (n=12) of the CVD 
group and 8.7% in the control group (n=4). The prevalence of peri-implant mucositis (no detectable bone loss 
beyond the initial physiologic bone remodeling) was found in 28.9% of the CVD group (n= 37) and 34.8% 
(n=16) in the control group. The prevalence of peri-implantitis defined by the presence of additional bone loss 
beyond the initial physiologic bone remodeling was found to be 65.9% (n=54) in the CVD case group and 
56.5% (n=26) in the control group. The crude odds ratio from the bivariate logistic regression for the association 
between peri-implantitis and CVD was 1.48 (95% CI = 0.71 to 3.11, p= 0.30). Alternatively, a significant 
association was found between peri-implantitis and CVD (crude odds ratio= 2.18, 95% CI= 1.02 to 4.67, p= 
0.04) when compared the prevalence of moderate to severe peri-implantitis (radiographic bone loss≥ 2mm). The 
prevalence of moderate to severe peri-implantitis, 48.8% (n=54) in the CVD group, was significantly higher 
than the 30.4% (n=14) in the control group. The overall peri-implant disease (peri-implant mucositis and peri-
implantitis) exhibited a similar prevalence between the two groups (90.2% vs 91.3%, p=0.84). The prevalence 




pocket depth (PPD) and BOP% was found in the CVD group (p> 0.05), especially with respect to bone loss> 4 
mm.  
 
The CVD group exhibited a significantly higher incidence of periodontitis (76.4%) compared to the healthy 
control group (48.9%) with an OR= 3.4 (95% CI= 1.52 to 7.52, P<0.01) (Table 6). The majority of disease 
severity observed in both groups was generalized Stage 2. Grade C was demonstrated in both groups with a 
prevalence of 71.8% in CVD group and 68.2% in the control group when the hsCRP level was considered. On 
the basis of indirect evidence (radiographic bone loss) and other direct evidence (e.g., case phenotype of biofilm 
deposition or smoking habits), Grade B was the majority finding, and a trend towards higher grades were 
observed in the CVD group (p=0.01). 
 
Tooth loss was significantly higher in the CVD group.  One-third of the participants lost more than 10 teeth, and 
another one-third lost 5-10 teeth. In the control group, half of the participants lost less than 5 teeth (p< 0.01). 
Implant-supported overdentures were more prevalent in the CVD group (14.6% vs 2.2%). Full edentulism in the 
CVD group was also significantly higher compared to the control group (12.2 vs 2.2%, p= 0.05). Interestingly, 
the frequency of maintenance among two groups showed no difference with similar prevalence between the 
episodic and the regular subgroups (p=0.23).  
 
Stratified analyses were performed based on different strata of age population. The association between 
moderate to severe peri-implantitis (radiographic bone loss ≥2mm) and CVD stratified by age were presented in 
Table 7. Without adjusting for any other factors (except gender), the estimates of odds of the association were 
2.31 (95% CI= 1.06 to 5.02, p=0.04) in the total population (range: 43-91 year old); and the gender-standardized 
significant association mainly existed in the 60-80 years old (OR= 2.46, 95% CI= 0.94 to 6.47, p=0.06). All age 
strata did not show a significant association after adjusting for smoking, hypertension, and family history of 
heart attack. Another stratified analyses was performed on the impact that DM and metabolic syndrome brought 
to the odds ratio for cardiovascular disease. Crude odds ratio for developing CVD was found to be statistically 
significant restricted to the strata of patients without DM (OR=2.29, 95% CI= 0.96 to 5.47, p=0.05); 
interestingly, the crude odds for CVD was significantly higher among subjects with metabolic syndrome 
(OR=3.5, 95% CI= 1.01 to 12.12, p=0.04). However, after adjusting for age, the significance was not observed 





For the results of step-wise multivariate logistic regression, at the first layer of regression model, odds ratio of 
moderate to severe peri-implantitis (radiographic bone loss ≥2mm) for CVD adjusting for single confounder 
including smoking (including quitting-year), alcohol, diabetes mellitus, BMI, metabolic syndrome, HDL level, 
hypercholesterolemia, or comorbidities remained significant. Among relevant covariates, age, hypertension, 
family history of heart attack, smoking, cLDL level, ASCVD risk, absence of periodontitis, and the number of 
tooth loss significantly impacted the association. Periodontitis and ASCVD had a dose-responsive effect. By 
fitting all potential risk factors into the final model of the moderate to severe peri-implantitis, a significant 
association was not observed after multivariable adjustments (Table 8).  
 






Seven serum biomarkers were tested to evaluate the association between peri-implant disease and CVD. The 
mean (median) values and significant differences between non-CVD and CVD group from the Kruskal-Wallis 
test results were presented in Table 9. The result showed that IL-1𝛽, TNF-𝛼 and fibrinogen were significantly 
higher in the CVD group compared to the non-CVD group (CVD vs. non-CVD: 97 vs 58.4 pg/ml, 104 vs. 56.5 
pg/ml, 86.2 vs. 62.3; respectively). Although not statistically significant, IL-6 and OPG demonstrated a trend of 
higher levels of detection in the CVD group. Conversely, the mean concentration of hsCRP was higher in the 
non-CVD group (CVD vs. non-CVD: 6.4 vs. 7.7 pg/ml).  
 
In the stratified subgroup analyses, the serum hsCRP concentration in the CVD group was higher than the non-
CVD among patients who had taken cholesterol-lowering medications (mainly statin therapy). Conversely, 
hsCRP was higher in the non-CVD group compared to CVD group among participants not taking statin therapy. 
The strata of participants with normal LDL-C level had similar hsCRP concentrations. However, hsCRP was 
higher in the non-CVD group restricted to participants with borderline to high cholesterol (LDL-C) (Table 10).  
 
The diagnostic ability was further assessed using chi-square analysis to predict the outcome of disease (CVD) 




performed to further assess at the continuous-variate level. Both tests demonstrated a significantly fair accuracy 
of disease prediction with TNF-𝛼 (AUC 67%) and fibrinogen (AUC 65%) for CVD (Table 11) (Figure 1). The 
results of Chi-square analysis based on the dichotomized data showed that IL-1𝛽, OPG, and TNF- 𝛼 were 
promising predictors for the CVD (sensitivity: 58.6%, 86%, 60% and specificity: 63.2%, 45.2, 65.8%; 
respectively) (Table 12). Further subgroup analysis was implemented to evaluate the predictive value of serum 
biomarkers in different subsets of chronic inflammation around dental implants. The results were summarized in 
Table 13. Fibrinogen was higher in the moderate to severe peri-implantitis group compared to the healthy 
implants (p=0.08), and CVD group was generally higher than the non-CVD group. A similar trend was observed 
in the IL-6, TNF-𝛼, and OPG when compared with peri-implant inflammation in the healthy sites. Serum 
biomarker levels were also evaluated to understand the association with the ASCVD risk classification among 
participants in the current investigation. IL-6 and TNF-𝛼 demonstrated a dose-response association (p> 0.05).  




128 implants were evaluated for the PICF. The results of the 12 biomarkers were shown in Table 14. TNF-𝛼 
exhibited a significantly higher detection level in the CVD group (p=0.05). The ROC curve analysis proved that 
PICF TNF- 𝛼 was a predictor for CVD, but with poor accuracy of prediction (AUC=59%) (Figure 2). Other 
PICF biomarkers including MMP-8, MPO, and IL-17 seem to be higher in the CVD group but without a 
significant difference (p>0.05). On the contrary, the level of PICF CRP, PGE2, IL-6, IL-8, TIMP-2 and VEGF 
appeared to be higher in the non-CVD group.  
 
In the subgroup analysis, MMP-8 proved to be significantly higher in the moderate to severe peri-implantitis 
(bone loss≥2mm) (3468.7 vs 3117.3 pg/ml, p=0.05). PGE2, IL-6, IL-17, MPO, OPG, TIMP-2, and TNF-𝛼 
demonstrated the same trend.  The abundance of these biomarkers displayed a higher level in the peri-
implantitis subgroup without reaching  significance. The local inflammation which manifested as peri-implant 
disease proved to be significantly associated with IL-1𝛽, MMP-8, and TIMP-2 (p< 0.05). MMP-8 was elevated 






Table 16 shows the mean values of GCF proteins collected from those teeth with periodontitis and teeth with 
healthy periodontium. in. CRP was higher in subjects with periodontitis compared to subjects with a healthy 
periodontium  (293.5 vs 276.0 pg/ml). A similar trend was also found in IL-6, MMP-8, and OPG. Only IL-1𝛽 
was statistically significantly higher collected from the periodontitis sites compared to the periodontal healthy 
sites (mean 160.2 vs. 119.3 pg/ml, p<0.01). VEGF exhibited a borderline significant difference (mean 97.5 vs. 
73.0 pg/ml, p=0.07).  
 
Comparison of GCF levels between case and control groups at different sites was shown in Table 17. In the 
subjects with periodontitis, either at sites of periodontitis or healthy periodontium, local gingival crevicular fluid 
TNF- 𝛼 was higher in the CVD group. This trend  with healthy periodontium, failed to reach significance. This 
pattern was not observed in other biomarkers. The predictability of GCF biomarkers associated with CVD was 
found in IL-6 collected from teeth with periodontitis in the dichotomized chi-square analysis, which is 5.7 in 
odds ratio (95% CI: 1.5-21.9, p<0.01). TNF-𝛼 collected from periodontitis teeth or healthy teeth in subjects with 
periodontitis was strongly associated with CVD cases with a sensitivity of 48.2% and specificity of 82.6% 
(p=0.01). The ROC curve analysis was illustrated in the Figure 3. If we compared  peri-implantitis alone, only 
GCF OPG was found to be significantly higher in the moderate to severe peri-implantitis subgroup collected 
from periodontitis teeth (52.2 vs 26.6 pg/ml, p< 0.04) even though the dichotomized prediction may not reach 
significance (p=0.13) (Figure 4). 
 
 
C. Microbial DNA profiles   
 
 
A total of 16 million (1.62E+07) sequence reads were obtained from the 16S next-generation sequencing (NGS) 
analysis. After quality trimming and filtration, there were 14243 final unique sequence reads. Taxonomy 
composition at the Phylum and Class level among case and control group were shown in supplemental Figures 2 
and 3 and Supplemental Table 1. Peri-implant pocket microbial community composition in the CVD group 
revealed higher percentages of Bacilli, Actinobacteria, and Gammaproteobacteria. Non-CVD group exhibited a 
higher percentage of Fusobacteria and Clostridia. The most common species in the total population was 
Fusobacterium nucleatum (13.6%), followed by  Streptococcus mitis-oralis-sanguinis (4.6%), Parvimonas mica 
(3.4%), Streptococcus intermedius (3.4%), and Veillonella parvula (3.1%) (Table 18). The microbial 




detected significantly more frequently in the CVD group (2.7 % vs 0.58%), and P. gingivalis was also found 
higher in the CVD group than the control (1.7% vs 1.0%). Contrastingly, Alloprevotella tannerae appeared with 
higher percentage in the healthy group, especially the healthy implant subgroups (1.8% vs 1.4%, case vs control, 
respectively). Linear discriminant analysis (LDA) algorithm (LEfSe) was used to estimate the effect the size of 
each differentially abundant trait, which ranks the phylotypes based on the relative differences between CVD 
and non-CVD groups, taking into account the variability and discriminatory power. The significantly abundant 
species discerned by the LEFse analysis were shown in the Figure 5. The CVD-related cluster was shown to be 
more associated with facultative anaerobic Actinomyces, and black-pigmented, Gram (-) anaerobic rods, 
Prevottella pallens. The most commonly found periodontal pathogens were summarized in Table 20.  
 
The "absolute abundance" generated from the NGS analysis was expressed in gene copies per microliter of each 
sample. The average gene copies per ml was higher in the samples among the CVD  group (1.4362x106/ml vs 
1.0029x106/ml, p=0.27) (Figure 6). The alpha diversity comparing the diversity within samples is shown in 
Figure 7. The median of the number of observed species was similar between two groups. The CVD group 
presented with a deeper sequencing depth, which represented  more taxa being identified at lower abundance. 
Beta diversity compared the diversity between samples, and is represented by a distance matrix algorithm 
(Principal Coordinates Analysis, PCoA). UniFrac plots were used to demonstrate the complex phylogenetically. 
This measured the phylogenetic distance between sets of taxa in the phylogenetic tree. samples with similar 
microbial composition profiles and closer to each other which represents the relatedness/similarity of samples, 
or clustering among samples. It was evident that CVD group exhibited a higher microbial diversity (Figure 8); 
and non-CVD group demonstrated a more clustered and centered profile. 
 
Finally, subgroup comparison is demonstrated in Figure 9.  The average absolute abundance (gene copies/ml) 
was significantly lower in the non-CVD group with healthy implants (4.3x105/ml) compared to the other three 
groups [significant difference compared to CVD + peri-implantitis group (14.5x106/ml) in Games-Howell post-
hoc test, p=0.03]. No species stood out for the LEFse analysis among 4 groups, only two species Lectotrichia 
goodfellowiii and Pseusomonas fluorescens fragi were significantly more abundant in the non-CVD with 
healthy implant group (Figure 10). The heatmap of 4 groups is presented in  supplemental Figure 4. 
Actinomyces oris, Prevotella pallens, and G(-) anaerobic cocci Veillonella, and Fusobacterium subspecies 




between CVD and non-CVD when the analyses only compared among peri-implant disease (or peri-implantitis) 
(Figure 11, 12) 
 
Beta-diversity among subgroups between case and control revealed a consistent observation that microbial 
profile in the subjects with CVD was more diverse; and the microbial profile of peri-implantitis also exhibited a 
higher dissimilarity compared to the healthy implant sites (Figure 13). This pattern of diversity of microbial 
profile comparing CVD to the non-CVD group was also observed in the peri-implant diseases (Figure 14). 
 
As a result, the 3 most common periodontopathogenic species P. gingivalis, T. forsythia, F. nucleatum found in 
the 16S sequencing results and S. aureus were selected for real-time qPCR to detect absolute bacteria counts for 
subgroup analysis. The Kruskal-Wallis test of bacterial load comparing case and control and subgroups was 
performed after the normality test (Table 21, 22). The absolute counts of these 4 species were not significantly 
different between the “case” and “control” groups. However, P. gingivalis demonstrated a trend towards higher 
counts in the CVD group.  Peri-implant pockets in the periodontitis subgroup harbored higher P. gingivalis 
compared to the healthy periodontal subgroup. The mean amount of gene copies of F. nucleatum was 
significantly higher in peri-implantitis group (radiographic bone loss ≥ 2mm) than the healthy group (p<0.05). A 
significant difference was also found between healthy implant and peri-implant diseases. T. forsythia was only 
found to be significantly higher in the severe peri-implantitis (radiographic bone loss >4 mm) group than the 
healthy implants (3.2E+07 vs 1.1E+07, p=0.01). The median and data dispersion (range) of these 4 species 
among healthy implant, mucositis, and peri-implantitis is demonstrated in Figure 15. S. aureus appeared to be 
an opportunistic species in the current investigation since only 4 samples found S. aureus at the DNA account of 
1.64E+04 gene copies. The characteristics of those patients were demonstrated in Table 23. There was a trend of 




II. Implant-level microbial and biomarker analysis 
 
An additional 10 patients with peri-implantitis were recruited to enhance the power of microbial profiles and 
biomarker discovery. A total of 142 participants were recruited and reported in this implant-level analysis. 




different peri-implant pocket depths (PPD), bone loss, presence/absence of suppuration, dentate/edentulous 
patients, and different stages of periodontitis. Absolute abundance (gene copies per ml) and PPD presented with 
a dose-responsive correlation, which was significantly higher in moderate pockets (4-6 mm), and even higher in 
deep pockets (≥ 7 mm) (Figure 16). The alpha diversity demonstrated higher species number can be found at 
peri-implant sites with moderate PPD than the deep PPD which was mainly composed by the anaerobic 
organismas (Corynebacteriaceae, Staphylococcae, Carnobacteriaceae, Neisseriaceae, Leptotrichiaceae, 
Burkholderiaceae, Pasteurellaceae, and Gammaproteobacteria). Deeper pockets harbored mainly 
Prevotellaceae, Eubactteriaceae and Erysipelotrichia and shallow pockets harboring more Euryarchaeota, 
Gram (+) rods, cocci, Actinobacteria, and Rickettsiales instead (Figure 17).  LEfSe analysis revealed the 
abundance species in three groups was illustrated in the Supplemental Figure 5. It can be related to the 
difference disclosed in the LDA Score comparison (LEfSe analysis) of bone loss level among subjects with peri-
implantitis (Figure 18). Tannerella forsythia, Bacteroidales, and Bacteroidia was found to be significantly 
abundant in the subjects with bone loss > 6 mm.  In contrast, Haemolysans sanguinis taiwanensis, Gemella, 
Bacillales family, and Lachnoanaerobaculum orale were more abundant the mild peri-implantitis (bone loss < 
2mm) sites. Absolute abundance also presented with a severity-dependent relationship that higher species 
numbers were observed at sites with higher severity. Suppuration was associated with a lack of keratinized 
mucosa (75%), and > 6 mm bone loss (50%). The abundant species found in peri-implant pockets with 
suppuration is shown in Supplemental Figure 6. Bacterial abundance was significantly higher at the sites with 
suppuration (Figure 19). It is noteworthy that beta-diversity plot demonstrated two cases with suppuration 
without detectable radiographic bone loss was at the area with least microbial diversity; which indicated the 
phylogenetic (tree) distance was significantly distant from those with bone loss (Figure 20). A higher bacterial 
count was discovered at the sites in fully edentulous patients compared to the dentate patients, especially at peri-
implantitis sites; however, bacterial diversity was found to be more diverse in those partial edentulous patients 
(Figure 21). In peri-implantitis sites in edentulous patients, Dietziaceae, Mitochondria family, and Rickettsiales 
were more frequently found (Figure 22). Finally, among those peri-implantitis sites with simultaneous presence 
of periodontitis on the remaining teeth, the microbial diversity within samples were found to be highest in the 
Stage 4 periodontitis when compared with Simpson's reciprocal index taking the richness and evenness of 
biodiversity into account (Figure 23). Although absolute abundance and beta-diversity seems to be similar 
among different severity of periodontitis, an unweighted PCoA revealed a clear clustering of samples, and the 




abundant species standing out among different severity of periodontitis using LEfSe analysis were presented in 
Supplemental Figure 7.  
 
Twelve biomarkers were analyzed using the Kruskal-Wallis test. The only significant difference  found between 
healthy implant and peri-implantitis sites was IL-17 due to the difference of data variance (variance 14.2 vs 44 
pg/ml). MMP-8 demonstrated a borderline significant difference between healthy implants and moderate to 
severe peri-implantitis (Table 24). MMP-8 further demonstrated a difference between healthy and peri-
implantitis when the more severe cut-off points of bone loss were adopted. The higher the peri-implant bone 
loss, the higher the difference of MMP-8 between healthy and diseased implants (3145 vs 36.28.3 pg/ml in PI 
with bone loss> 4mm, p=0.05). PGE-2 showed the significant higher value in peri-implantitis until the bone loss 
cut-off point reached 3mm (147.2 vs 11.5.3 pg/ml, p=0.03). Lastly, when examining peri-implant inflammation 
(including mucositis) versus the healthy peri-implant sites, the positive association between biomarkers and 
peri-implant disease could be observed in the value of IL-6, IL-1𝛽, IL-8, MMP-8, TIMP-2, and PGE2. IL-6 was 
the only biomarker that was not significant (Table 25).  
 
Further ROC analysis explored the diagnostic value of these biomarkers. PGE-2 had significant diagnostic 
accuracy (AUC=57%) for a more severe form of peri-implantitis (> 4mm bone loss; Figure 25). MMP-8 had 
significant diagnostic accuracy (AUC=62%) for severe peri-implantitis (>4mm bone loss; Figure 26). The 
highest predictive ability for discerning healthy implant and peri-implant disease (Figure 27) was with IL-1𝛽 
(AUC 70%), IL-8 (AUC 70%), MMP-8 (AUC 73%), TIMP-2 (AUC 74%), and PGE2 (AUC 69%). Lastly, chi-
square test of the dichotomized prediction was performed to confirm the accuracy for moderate to severe peri-
implantitis. The only significant predictor was IL-1𝛽 (p=0.02). For detecting peri-implant disease, a significant 
association of TIMP-2 and PGE2 was reported, while IL-1𝛽 and MMP-8 presented with borderline significance. 
(Table 26).  
 
P. gingivalis, T. forsythia, and F. nucleatum were tested for  association with disease manifestation using ROC 
analysis. All three species reached significance for the prediction of severe peri-implantitis. Bacterial counts 
were higher in the more severe form of peri-implantitis. AUC was 100%  predictive of peri-implant 
inflammation (Figure 28) (Table 27). Dichotomized chi-square test was performed. F. nucleatum demonstrated  




significance. P. gingivalis demonstrated  borderline significant prediction in peri-implant disease (Table 28). A 
combined prediction model was analyzed to predict peri-implant disease. T. forsythia and F. nucleatum 
demonstrated  significant predictive ability combined with PICF biomarkers of MMP-8, IL-1𝛽, and TIMP-2 
with a higher predictive sensitivity and specificity compared to protein biomarkers alone. For differentiation of 
moderate to severe peri-implantitis, only F. nucleatum presented with significant sensitivity (approximately 
70%) when combined with three protein biomarkers (Table 29). 
 
Finally, GCF collected from the patients with periodontitis consistently demonstrated a significant difference 
between peri-implantitis and healthy sites with two cytokine biomarkers. OPG from periodontitis pockets 
(59.7±90.9 vs 26.6±51.6 pg/ml, p=0.01) and IL-6 from healthy sites on periodontitis patients (4.46±11.3 vs 
1.56±0.86 pg/ml, p=0.04) was detected with higher levels at peri-implantitis group compared to the healthy 
implant group. Sensitivity and specificity of OPG and IL-6 to predict peri-implant disease was 48.9%, 56.5% 
and 17%, 79.2% respectively. These two biomarkers from healthy sites on periodontitis patients also 
demonstrated similar patterns associated with peri-implant diseases. TIMP-2 collected from periodontitis 
pockets was shown to be higher at peri-implant disease (PID) group than the healthy implant group 
(1420.5±583.4 vs 1082.2 ±458.4, p=0.04) with the sensitivity and specificity of 43.8% and 66.7%. Other GCF 
biomarkers didn't reveal any patterns related to  peri-implant disease. For subjects with periodontitis, only IL-1𝛽 






Chapter V. Discussion 
 
 
To the author's knowledge, this is one of the first investigations examining the association between peri-
implantitis and cardiovascular diseases (CVD). In order to evaluate the potential risks low-grade chronic 
inflammation from peri-implantitis may pose to CVD, participants in the "Case" CVD group were rigorously 
recruited following the criteria that the dental implants were placed prior to CVD diagnosis (or cardiac event) 
being established. More importantly, the presence of peri-implantitis was evidenced radiographically before the 
CVD was diagnosed to ensure the temporal relationship between "exposure" and "disease". This case-controlled 




p= 0.30). In order to discern the inflammatory burden of peri-implantitis and to decrease the probability of false 
positives, a more definitive criteria of moderate to severe peri-implantitis (BOP ± suppuration and radiographic 
bone loss ≥2mm) was implemented (Sanz et al. 2012; Derks et al. 2016). Moderate to severe peri-implantitis 
was significantly associated with the risk for CVD with an odds ratio of 2.18 (p=0.04). This significant 
difference persisted after adjusting for gender, and remained  borderline significant at the stratum of 60 to 80 
years of age (OR=2.5, p=0.06). Traditional risk factors for CVD were scrutinized in this investigation, The 
association between moderate to severe peri-implantitis and CVD after the adjustment for single confounders 
including smoking, alcohol, diabetes mellitus, BMI, metabolic syndrome, HDL level, hypercholesterolemia, or 
comorbidities remained significant. However, after controlling for all significant confounders, including age, 
smoking, hypertension, family history of heart attack, and the presence of periodontitis in the final multivariate 
logistic regression model, the significant association was no longer observed (adjusted OR= 1.36, p=0.54).  
 
Atherosclerosis is an inflammatory process involving the host's immune mechanism interacting with other 
conventional risk factors to initiate, disseminate, and activate lesions throughout the cardiovascular system 
(Bentzon et al. 2014; Herrera et al. 2020). However, it cannot be fully explained by classical risk factors (Katz 
et al. 2001). Evidence has emerged demonstrating that low-grade chronic inflammation is not only associated 
with the increased prevalence of cardiovascular risk factors, but is also an independent risk factor for the 
development of CVD (Danesh et al. 2000; de Rooij et al. 2009; Koenig 2018). A number of chronic 
inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematous, ankylosing spondylitis, 
Sjögren's syndrome, polymyalgia rheumatica, inflammatory bowel disease, and psoriasis are associated with an 
increased risk of CVD (Haque et al. 2008; Coumbe et al. 2014; Ogdie et al. 2015; Agca et al. 2017; Eriksson et 
al. 2017; Feng et al. 2017; Ungprasert et al. 2017; Yong et al. 2018). Periodontitis, consistent with the rationale 
that chronic elevation in the systemic inflammatory burden was reported causally related to CVD development 
and its sequelae(Orlandi et al. 2020; Schenkein et al. 2020). Proposed mechanisms explaining the association 
between periodontitis and CVD include bacteremia and the associated systemic inflammatory cascades, 
including elevations in C-reactive protein and oxidative stress (Schenkein and Loos 2013; Herrera et al. 2020).  
 
Peri-implantitis is considered a biological complication after dental implant placement (Heitz-Mayfield et al. 
2014), exhibiting signs of inflammation and increased pocket depths over time. Peri-implantitis is a 




bone volume, implant proximity, 3-D implant position, and prosthetic design), local factors (history or ongoing 
compromised status of periodontitis, poor oral hygiene, and episodic periodontal maintenance), and host-factors 
(smoking, diabetes, immune susceptibility) (Berglundh et al. 2018; Schwarz et al. 2018). Given the similarities 
between peri-implantitis and periodontitis, the biological plausibility that chronic inflammation  arisen from the 
continuously overwhelming bacterial insult  propagates to distant tissues may be shared. The risk for 
atherothrombogenesis was identified in the higher levels of inflammation around dental implants with bone loss 
more than 2mm in the present study. Interestingly, the significant association with CVD seemed to emerge 
mainly in patients without diabetes, yet not in patients with metabolic syndrome in the current results. After 
controlling for significant confounding effects from age, hypertension, and family history, the probability for 
CVD remained higher but lost the statistical significance. It can be surmised that the impact from local 
inflammation is more evident among non-diabetic individuals, who were less likely under the influence of 
hyperglycemia with multiple comorbidities and increased risk for CVD(Leon and Maddox 2015). Instead, 
subjects with metabolic syndrome are inherently exposed to a cluster of risk factors for CVD. It is arguable that 
the local inflammation around dental implants had less influence on the potential propagation of inflammation 
compared to the pre-existing systemic inflammation burden originating from poor glycemic control, visceral 
obesity, metabolic syndrome, hypertension, lipid protein, and health behaviors (such as alcohol intake and 
smoking habits).  
 
Inflammation and infection induce a variety of alterations in lipid metabolisms that may initially suppress 
inflammation or fight infection. However, chronic inflammation could contribute to the increased vascular 
inflammation and atherosclerosis (Khovidhunkit et al. 2004). The most common changes in lipid profiles related 
to the low-grade chronic inflammation are the decreases in HDL cholesterol and increases in triglycerides due to 
an increase of hepatic VLDL production and a decrease in the clearance of triglyceride-rich lipoproteins 
(Feingold and Grunfeld 2019). Dyslipidemia with consequent increases in pro-inflammatory lipid classes, along 
with common genetic susceptibility factors, leads to  escalated inflammatory responses (Reyes et al. 2013; 
Schenkein and Loos 2013). Overall, the percentage of participants recognized as hypertriglyceridemia was 
higher in the non-CVD group compared to the CVD group (13.5% vs 6%). There were 51% participants in the 
non-CVD group with LDL-C levels above normal. On the contrary, only 22% of CVD group were found to be 
above normal levels. Nevertheless, the higher percentage (34%) of participants among the CVD group revealed 




the non-CVD group exhibited a predisposition to dyslipidemia which may partly account for the inflammatory 
profile among participants in the two groups and may impact the association between the two diseases. The 
difference of lipoproteins between the case and control groups may be explained by the overwhelming use of 
statin in the CVD group (60%) compared to the non-CVD group (28%). Statin (HMG-CoA reductase inhibitors) 
can effectively reduce the circulating levels of atherogenic LDL via regulation of LDL receptors (Nissen et al. 
2005; Kinlay 2007). The clinical success has been confirmed by the meta-analysis of large randomized trials 
and has proven that atherosclerosis progression is attributed to the elevated LDL (Baigent et al. 2005; Baigent et 
al. 2010). Investigations have shown that statins are anti-inflammatory and are associated with reduced serum 
markers of inflammation (hsCRP), reduced T-cell and monocyte activation, and reduced blood clotting (Quist-
Paulsen 2010). The effect of statins on HDL increase is modest and independent of LDL-C level (McTaggart 
and Jones 2008; Barter et al. 2010), which may explain the results we observed in the current dataset.  
 
It was no surprise that the concentration of serum pro-inflammatory biomarkers in the present study including 
IL-1𝛽, TNF-𝛼 and fibrinogen were higher in the CVD group independent of the local peri-implant inflammatory 
status. IL-6 and OPG also demonstrated a similar trend towards elevated biomarkers among participants with 
CVD. Interleukins mediating the signaling of leukocytes contribute profoundly to the atherosclerosis process 
(Dinarello 2011). IL-1𝛽 is strongly associated proatherogenic properties including the upregulation of 
endothelial adhesion and activation of macrophages and vascular cells (Clarke et al. 2010; Ait-Oufella et al. 
2011). Notable effects of IL-1ß include the induction of prostaglandin production through induction of 
cyclooxygenase-2 (COX-2), the elaboration of nitric oxide, and activation of innate immune cells (Libby 2017). 
Not only does the increased IL-1𝛽 trigger a series of inflammatory reactions to promote bone resorption, IL-1𝛽 
blockage has become the therapeutic strategy for autoinflammatory diseases such as T2DM, rheumatoid arthritis 
(RA), and gout (Cheng et al. 2020). Polymorphism of the IL-1 gene cluster is associated with severe 
periodontitis(Brodzikowska et al. 2019). Furthermore, IL-1RN gene polymorphism has been shown to be a risk 
factor for peri-implantitis (Laine et al. 2006).  
 
Among cytokines, TNF-𝛼 and IL-6 are implicated in chronic inflammatory diseases. They are known for 
modulating immune reactions and acute response phase in inflammation (Le and Vilcek 1989) and secreted in 
response to stress hypoxia and tissue destruction which lead to cardiac cachexia after ingestion of apoptotic cells 




al. 2007) and human (Moreau et al. 2013) models contributing to vascular dysfunction. More importantly, it has 
been shown that TNF-𝛼 upregulates the oxidative stress via increased production of reactive oxygen species, 
which has been linked to arterial stiffness in the aged population (Moreau et al. 2006) where increased 
adiposity-induced inflammation and comorbidities are more prevalent (Carter et al. 2018). IL-6 derived from T 
lymphocytes, macrophages, and adipocytes, together with IL-1 and TNF-𝛼 have been found to be the key 
players at the downstream of vascular inflammatory cascade of accelerating atherosclerosis (McInnes et al. 
2015). Also, the risk of future myocardial infarction among healthy men has been shown most likely related to 
plaque instability (Ridker et al. 2000; Anderson et al. 2013). IL-6 and TNF-𝛼 have been reported to be 
consistently increased in patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) since 
both play the central roles in the systemic inflammatory reactions (Hernández-Rodríguez et al. 2003; Sattar et al. 
2003; Umare et al. 2014). These evidences coincided with the results of the current investigation that IL-6 and 
TNF- 𝛼 demonstrate a fair predictive ability of CVD, as well as a dose-responsive association with the 10-year 
ASCVD risk.  
 
Fibrinogen is inherently low in serum, since the coagulants are present mainly in plasma. Yet, the unified 
protocol of serum collection without the anticoagulants in all samples may allow for more standardized results, 
especially when multiplex immunoassay are analyzed (Tuck et al. 2009). The concentration of fibrinogen 
detected in the current investigation was approximately 60 mg/dl, which was much lower than the normal level 
in plasma (200-400 mg/dl). Still, by high-sensitivity ELISA array designed for serum samples, the significant 
difference of fibrinogen between CVD and non-CVD group was appreciated and showed a fair predictive ability 
of an AUC 65% in the ROC analysis. Elevated levels of fibrinogen in serum have been related to increased 
blood viscosity and thrombus formation; and a positive association between plasma fibrinogen and CVD, 
independent of other atherogenic factors and antithrombotics such as aspirin, has been reported (Kannel et al. 
1987; Ma et al. 1999; Palmieri et al. 2003). In a meta-analysis of a large number of individuals, a moderate 
association has been found between fibrinogen levels and the risk of CHD, stroke, and other vascular mortality 
(Danesh et al. 2005). Recently, among the growing number of molecules for potential utility as CVD 
biomarkers, much attention has been centered on osteoprotegerin (OPG) and its ligands, including the receptor 
activator of nuclear factor kB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL) (Hofbauer 
and Schoppet 2004). OPG, a regulatory protein for bone metabolism and vascular calcification, has been found 




mortality and morbidity (Jono et al. 2002; Lieb et al. 2010). There is a strong evidence of correlation between 
the RANK-RANKL-OPG system and the atherosclerotic plaque calcification(Dhore et al. 2001; Schoppet et al. 
2004). The immunological process of atherosclerosis has been shown to be related to increased expression of 
RANKL from T-cell that increases in leukocyte response and matrix degradation, leading to plaque 
destabilization (Shaker et al. 2010). OPG as a decoy receptor of RANKL may behave as an anti-inflammatory 
mediator and inhibit TRAIL-associated apoptosis in susceptible endothelial cells. The serum concentration of 
OPG in the current results corresponded to the ASCVD 10-year risk; which was in agreement with previous 
observations that it is a promising biomarker for ASCVD, regardless of conflicting data about the potential 
cardioprotective role(Özkalaycı et al. 2018). Lastly, serum hsCRP didn't show the significant difference and 
demonstrated an inverse relationship with the CVD group. The discussion of this finding is listed in the 
Supplement Table 2. 
 
The evidences of biomarkers accumulated for peri-implant disease are mainly focused on PICF proteins rather 
than systemic markers in serum (Faot et al. 2015; Ghassib et al. 2019). In general, they are in concordance with 
the current results, that PGE2, IL-1𝛽, IL-6, IL-8, OPG, TNF-𝛼, MMP-8, VEGF, and TIMP-2 were in higher 
concentrations at inflammed peri-implant sites; but only PGE2, IL-1𝛽 MMP-8, and TIMP-2 reached the 
statistical significance. In the comparison between healthy implants and moderate to severe peri-implantitis, 
only MMP-8 reached a borderline significance (3387 vs 3104 pg/ml, p=0.09). To summarize, four PICF 
biomarkers (PGE2, IL-1𝛽, MMP-8, and TIMP-2) were demonstrated in the current investigation to be strong 
predictors for the peri-implant inflammation. However, the ability to differentiate the peri-implantitis with mild 
bone loss was not strong enough to reach statistical significance. Only the severe form of peri-implantitis 
manifested with a significantly higher concentration of MMP-8. Overall, locally PICF biomarker did not 
demonstrate a capacity to differentiate between CVD and non-CVD group. Only TNF-𝛼 was predominantly 
higher in the CVD group, and coincided with the local peri-implant inflammation. TNF-𝛼 has been reported as 
the most common cytokine isolated from patients with peri-implantitis (Konttinen et al. 2006). Interestingly, it 
has been correlated with severe peri-implantitis and reduced significantly comparable to the control sites 3 
months after the mechanical anti-infective therapies (de Mendonça et al. 2009; Duarte et al. 2009b). TNF-𝛼 
underlines the real-time manifestation of inflammation; and when the fibroblasts in the chronic peri-implantitis 




leukocytes may occur continuously within the sites in a self-feeding loop (Bordin et al. 2009), which may 
explain why the results in current study coincided with the systemic inflammatory burden.  
 
The correlation of PGE2 with clinical manifestations of periodontal and peri-implant inflammation has been 
shown in cross-sectional studies (Heasman et al. 1998; Preshaw and Heasman 2002; Yalçn et al. 2005). It is in 
agreement with the current investigation that predictability for peri-implant inflammation was with AUC=69% 
and significantly higher in the severe peri-implantitis group. This implied that the severe peri-implantitis sites 
have higher vasodilation, increased vascular permeability, activation of osteoclasts, and mediation of bone 
resorption (Offenbacher et al. 1993).  This is in agreement with the report that elevated PGE2 and MMP-8 are 
correlated with the peri-implant mucosa inflammation and pocket depth increase, especially MMP-8 which 
appears to be an early signal of peri-implant inflammation (Basegmez et al. 2012). MMPs have been 
collectively related to the degradation of the extracellular matrix and basement membrane during tissue 
destruction and remodeling (Ryan and Golub 2000) which manifests in the cases in peri-implant disease. In 
addition, MMP-8 as a neutrophil collagenase, has been shown to be triggered by potent periodontopathogenic 
bacteria and their virulence factors (Sorsa et al. 2016). Thus, elevated MMP-8 has been shown significantly 
associated with soft and hard tissue destruction such as in periodontitis and peri-implant disease (Teronen et al. 
1997; Nomura et al. 1998; Nomura et al. 2000; Xu et al. 2008). Furthermore, the concentration of MMP-8 is 
correlated to the severity of peri-implant bone loss (Ma et al. 2000; Kivelä-Rajamäki et al. 2003). The strong 
predictive ability of MMP-8 as an adjunctive diagnostic tool has been reviewed in the literature (Al-Majid et al. 
2018; Ghassib et al. 2019). This is consistent with the current findings that the predictability was 62% for severe 
peri-implantitis (bone loss >4mm) and 73% for peri-implant inflammation, respectively. It was noteworthy that 
it demonstrated a significant sensitivity to predict moderate to severe peri-implantitis when combined with T. 
forsythia and F. nucleatum and the power was higher compared to the prediction model restricted to biomarker 
or microbial profile alone. Tissue inhibitor of metalloproteinases-2 (TIMP-2) is known for its ability to inhibit 
protease activity and suppression of endothelial cell proliferation (Stetler-Stevenson 2008). Its anti-
inflammatory and anti-catabolic features have been shown in a comparative study. After non-surgical treatment 
of peri-implantitis sites, increased expression of TIMP-2 is detected (Ghighi et al. 2018). A disruption of the 
MMP-TIMP balance may lead to a pathological process of losing ECM, such as arthritis, atherosclerosis, and 
periodontitis. An elevated expression of TIMP-2 has been reported in chronic periodontitis and is elevated even 




TIMP-2 behaves as an effective predictor of peri-implantitis (OR= 4.4). When the diagnostic tool is combined 
with the microbial profile of T. denticola, the power of prediction increases (Wang et al. 2016). However, such 
trend was not appreciated in the current results. Additional discussion pertaining to the non-significant findings 
of OPG, IL-6, IL-8, and VEGF is listed in the Supplemental Table 3. 
 
Evidence suggests that oral bacteria can enter the blood stream and cause bacteremia either following daily 
toothbrushing, chewing or professional interventions (periodontal probing, scaling, or surgical extraction) 
(Balejo et al. 2017) and is fundamentally associated with the gingival inflammation (Tomás et al. 2012). 
Furthermore, periopathogenic pathogens have been identified in the atherosclerotic plaques (Mahendra et al. 
2013; Armingohar et al. 2014). Viable P. gingivalis and A. actinomycetemcomitans have been discovered in 
atherothrombotic lesions within atheroma samples(Kozarov et al. 2005; Rafferty et al. 2011). Particularly, P. 
gingivalis has been shown to accelerate atherosclerosis in murine models and induce aortic and coronary lesions 
after bacteremia in normocholesterolemic pigs (Schenkein and Loos 2013). In vitro evidence also supports the 
importance of the fimbriae of P. gingivalis to adhere and enter human coronary endothelia cells and to promote 
atherothrombotic lesions (Bélanger et al. 2012; Yang et al. 2014). P. gingivalis, A. actinomycetemcomitans, T. 
denticola, and T. forsythia in subgingival plaque samples have been reported to be associated with carotid 
intima-media thickening in the adjusted analysis of a large population study (Desvarieux et al. 2005). Recently, 
a polymicrobial experimental infection (P. gingivalis, T. forsythia, T. denticola, and F. nucleatum) has been 
shown to induce the aortic toll-like receptors (TLRs) and inflammasome signaling and enhance the oxidative 
stress reaction within the aortic endothelial cells (Velsko et al. 2014; Chukkapalli et al. 2015). Commensal 
pathogen, F. nucleatum, can turn to periopathogenic which has been linked to acceleration of aortic 
atherosclerosis in an apolipoprotein E (ApoE)null hyperlipidemic mice model (Han 2015; Velsko et al. 2015). It 
has been implicated in the association with CVD (Han and Wang 2013). Additionally, it has been detected in 
ruptured cerebral aneurysm (Ford et al. 2006; Figuero et al. 2011; Pyysalo et al. 2013) and related to the severity 
of periodontitis (Elkaim et al. 2008).  
 
The microbial DNA sequencing profile established in the current investigation demonstrated the relative 
abundance of P. gingivalis was higher in the CVD group (1.7% vs 1%). Subsequent PCR analysis also showed 
absolute bacterial counts of P. gingivalis was higher in the CVD group (5.3E+07 vs. 3.9E+07). The same 




gingivalis was in agreement with the previous findings. Another interesting finding was that higher CRP 
detection in peri-implant sulci was associated with the higher detection frequency of P. gingivalis, which may 
be correlated to the intricate link between inflammatory challenge by local bacterial insult and the cross-talk 
with the systemic inflammatory mediators. Secondly, our results showed peri-implant pockets appeared to 
harbor higher concentrations of F. nucleatum in a dose-responsive fashion associated with the severity of peri-
implantitis. Although the magnitude failed to fully correspond to the severity of the disease, higher counts of P. 
gingivalis and T. forsythia were found at peri-implant inflamed sites compared to the absolute healthy peri-
implant sites. T. forsythia has been reported as the most frequently detected species with the increased 
magnitude of peri-implant disease (Charalampakis et al. 2012). On the other hand, F. nucleatum and P. 
gingivalis are correlated to the implant sites with the deepest probing depth (Renvert et al. 2007). Our 
observation was consistent with a variety of reports in peri-implantitis with regard to the predominance of these 
three species and a more divergent profile of the microbial community compared to chronic periodontitis 
(Mombelli 2002; Shibli et al. 2008; Pérez-Chaparro et al. 2016; de Waal et al. 2017; Lafaurie et al. 2017; 
Schwarz et al. 2018; Costa et al. 2019; Sahrmann et al. 2020). Peri-implant PD > 5mm with concomitant BOP, 
along with a full-mouth plaque scores> 20%, are generally considered as major risk factors for the peri-
implantitis (Heitz-Mayfield et al. 2014; Heitz-Mayfield et al. 2020). Our results supported the observations that 
predominantly anaerobic microorganisms at peri-implantitis niche are associated with deeper pockets and severe 
bone loss (Augthun and Conrads 1997; Cortelli et al. 2013). T. forsythia especially stands out in the lesions with 
bone loss > 4mm. Partial edentulous individuals have been reported to potentially harbor more pathogens 
compared to those fully edentulous subjects in a recent systemic review (de Waal et al. 2014). Data from this 
study also indicated that partial edentulous individuals were found to harbor a more divergent composition of 
the microbial community. However, P. gingivalis, T. forsythia, and F. nucleatum were found to be higher in the 
edentulous subgroup (p<0.01 in the difference of T. forsythia). Prudent interpretation should be advised since 
our sample size for total edentulous patients was limited (n=10). 
 
Due to the complexity of the microbial community of the samples in the current investigation, it was difficult to 
conclude a certain pattern of predominance of species between case and control groups. Yet, an interesting 
finding of this study was that Haemophilus parainfluenzae was detected more frequently in the CVD group 
(2.7% vs 0.6%). Haemophilus parainfluenzae, one of the HACEK organisms commensal to the human oral 




pneumonia (Duzenli et al. 2017). Another opportunistic pathogen found in the current observation which is 
strongly associated with infective endocarditis (IE), was S. aureus. It is the most common pathogen entering the 
blood stream and has accounted for 31.4% of definite IE reported in a large prospective-cohort study most 
commonly found related to health care (39.1%) (Fowler et al. 2005). It has been reported as nosocomial 
infections in IV drug users and prosthetic valve recipients (Miro et al. 2005). New at risk categories for S. 
aureus infections include increased patient age, elevated drug resistance, intensive treatment such as renal 
hemodialysis, immuno-suppression, long-term indwelling central venous catheter, and the application of 
modern cardiac device implants (Hoerr et al. 2018). It has been viewed as one strongly relative pathogen in the 
chronic infection around dental implants (Mombelli and Décaillet 2011; Persson and Renvert 2014) and has 
been shown to colonize implants early after placement (Fürst et al. 2007) and persists long-term (Salvi et al. 
2008). It has been associated with deeper peri-implant pockets or suppurative failing implants in some 
reports(Leonhardt et al. 1999; Kronström et al. 2001; Albertini et al. 2015). This is consistent with observations 
in this study. The susceptibility of S. aureus infection is not clear, since there is a lack of humoral immunity 
factors involved in osseointegration (Kronström et al. 2000; Albertini et al. 2015) and the affinity of S. aureus to 
titanium (Harris et al. 2007). There is a disparity in the reports of S. aureus in peri-implantitis sulci by DNA-
DNA checkboard (Renvert et al. 2007; Renvert et al. 2008; Salvi et al. 2008; Persson and Renvert 2014) or 
culture techniques (Canullo et al. 2016; de Waal et al. 2017). However, there are only few studies that identify 
S. aureus in the peri-implantitis sites using the RT-qPCR. The higher detection frequency reported by Zhuang et 
al. compared to the current study may be attributed to the primer design targeted to a different strain (Mu3 as 
opposed to Sau31 strain) and the study design differences (within-same-subject comparison) (Zhuang et al. 
2016). On the contrary, the result from Canullo et al. using qPCR is in line with our results showing  S. aureus 
was detected in very low bacterial counts (Canullo et al. 2015). 
 
In conclusion, it is reasonable to extrapolate the same biological mechanisms of chronic periodontitis to the 
chronic peri-implantitis which shared some similarities of low-grade chronic inflammation at gingiva/mucosa 
tissue, including the soft tissue reactions to plaque formation, such as the B and T-cell-dominated inflammatory 
cell infiltrates and tissue breakdown (Sanz et al. 1991; Zitzmann et al. 2001; Konttinen et al. 2006; Salvi et al. 
2012), and the similar microbiologic niche harboring key common anaerobic periodontopathogens, such as P. 
gingivalis, F. nucleatum and T. forsythia (Mombelli 2002; Koyanagi et al. 2013; Persson and Renvert 2014; de 




plausibility that low-grade chronic inflammation around diseased dental implants, especially when the disease 
severity and tissue destruction increased, may have an implicit role in the manifestation and progression of 
atherosclerosis and subsequent cardiovascular sequelae. The results in the current investigation showed an 
increasing amount of TNF-𝛼 in the CVD group that coincided with the local peri-implant inflammation. This 
suggests that the low-grade chronic inflammation may be the common denominator between CVD and peri-
implantitis and among the shared risk factors/indicator for these two diseases. 
 
The limitations of current investigation included the lack of ability to establish the causality of these diseases in 
this case-control design, cross-sectional study. Secondly, confounding bias cannot be ruled out because the case 
of CVD was established regardless of the disease severity and the time elapse since the diagnosis. Albeit the 
association between peri-implantitis and CVD was lessened to a non-significant relationship after controlling for 
multiple cofounders, the result of current report might present the influence of a risk indicators of peri-implant 
disease for the CVD on the sub-elements of disease manifestation. It emphasizes the need of both clinical and 
radiographic evaluation of dental implants on a regular basis to reduce the concomitant risks for CVD and also 
sheds light on the need for future research to understand the complex inter-relationship between local 
inflammation around dental implants and the systemic inflammatory burden to cardiovascular risk.  
 
 
Chapter VI. Future Research Direction 
 
The result of current investigation revealed an association of CVD to a more severe manifestation of peri-
implantitis, and the escalated level of pro-inflammatory cytokines observed in our findings supported the 
hypothesis that consistently chronic peri-implant inflammation may pose a higher risk for the development of 
CVD. Such association seems to augment as the severity of disease increased; however, the association was not 
found in the severe peri-implantitis which may related to the limited sample size in that stratum. Therefore, 
future studies with a larger sample size were warranted; moreover, to control for possible patient-related 
confounders with age- and gender-matched design and relevant implant-related factors with same settings such 





The relationship between the prevalence of P. gingivalis around diseased implants and CVD also called for 
more future human studies to illuminate the potential causal relationship between the peri-implant disease and 
CVD.  Lastly, as the case-control design may provide a higher power of evidence compared to the cross-
sectional study to establish that peri-implantitis was a risk indicator for the cardiovascular disease; however, 
future cohort longitudinal studies were warranted to explore the possibility that chronic inflammation around 
dental implants may be a true risk factor for the cardiovascular disease.  
 
 
Chapter VII. Conclusion 
 
The present study assessed the odds of peri-implantitis as a possible risk indicator for the cardiovascular disease. 
The statistical analyses indicated that the association between peri-implantitis and cardiovascular disease was 
strongly influenced by the selection of threshold of bone loss defining disease severity. The moderate to severe 
form of peri-implantitis was significantly associated with cardiovascular disease (odds ratio 2.18). Although it 
remained borderline significant association among individuals between 60 to 80 years of age after controlling 
for gender, but a null association was observed after adjustment for multiple significant confounding factors.  
 
The low-grade chronic inflammation around diseased dental implants, especially when the disease severity and 
tissue destruction increased, may be a factor relating these two diseases. The result of the current investigation 
sheds light in understanding the relationship between peri-implant chronic inflammation and cardiovascular 
diseases.  Future study should include a prospective clinical trial that follows patients with peri-implantitis for a 
period of time and see if the disease eventually leads to the development of cardiovascular disease.  
 
 
Chapter VIII. Tables and Figures 
 Table. 1 Epidemiologic evidence of the relationship between cardiovascular disease and peri-implantitis 
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Table 2. Demographic variables and CVD risk factors  
  
Variable 
non-CVD (n = 46) 
n [%] 
CVD (n =82) 
n [%] 
P Value 
   Age  [mean ± SD (range)] 69.3 ± 10.1 (43-86) 75.0± 8.3 (50-91) 0.004 § 
Age 40-49 y 3  (6.5) 0 (0) <0.01 
 50-59 y 2 (4.3) 5 (6.1)  
  60-69 y 16 (34.8) 12 (14.6)   
 70-79 y 17 (37.0) 41 (50)  
 ≥ 80 y 8 (17.4) 24 (29.3)  
Gender   0.08 
  Female  23 (50) 28 (34.1)   
 Male  23 (50) 54 (65.9)  
Ethnicity     0.08 
 White   36 (78.3) 74 (90.2)  
  Black  3 (6.5) 3 (3.7)   
 Hispanic  3 (6.5) 0 (0)  
  Asian or other  4 (8.7) 5(6.1)   
Smoking   0.03 
  Never-smoker  28 (60.9) 30 (36.6)   
 Current smoker  2  (4.3) 4 (4.9)  
  Ex-smoker   16 (34.8) 47 (57.3)  
           <=5 years  1 (6.3) 3 (6.3) 0.52 
            5-10 years  2 (12.5) 3 (6.3)   
           10-15 years  2 (12.5) 2 (4.2)  
            >15 years  11 (68.8) 40 (85.1)   
Alcohol   0.59 
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(142 user/586 non-users) 
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 Social drinker  15 (32.6) 17 (20.7)  
  <7 units /week   12 (26.1) 21 (25.6)   
 7-14 units /week  4 (8.7) 9 (11)  
  >14 units /week  0 (0) 1 (1.2)   
BMI    0.85 
  Normal  17 (37) 23 (28)   
 Overweight  15 (32.6) 30 (36.6)  
  Obese  12 (26.1) 21 (25.6)   
 Severe Obese   2  (4.3) 3 (3.7)  
Metabolic Syndrome  20 (43.5) 45 (54.9) 0.22 
Diabetes Mellitus¶  8 (17.4) 24 (29.3) 0.14 
Hypertension¶  18 (39.1) 49 (59.8) 0.03 
High Cholesterol¶ 16 (34.8) 38 (46.3) 0.20 
Osteoporosis or bone-related disease¶  7 (15.2) 15 (18.3) 0.64 
Rheumatoid arthritis¶ 3 (6.5) 6 (7.3) 0.87 
Co-morbidity       
 1 co-morbidity  14 (30.4)  27 (32.9) 0.77 
  2 co-morbidity   10 (21.7)  17 (20.7) 0.89 
 3 co-morbidity 9 (19.6)  25 (30.5) 0.18 
Family Health History       
 Heart Attack  17 (37) 48 (58.5) 0.01 
  Stroke  21 (45.7) 29 (35.4) 0.33 
 Hypertension  25 (54.3) 48 (58.5) 0.46 
  Diabetes  18 (39.1) 40 (48.8) 0.27 
 Cancer  28 (60.9) 52 (63.4) 0.62 
Medications    
 Hypoglycemics 5 (10.9) 20 (24.4)  
 Aspirin 11 (23.9) 37 (45.1)  
 Anticoagulant 2 (4.3) 28 (34.1)  
 Statin  13 (28.3) 49 (59.8)  
 Angiotensin II receptor blocker 8 (17.4) 16 (19.5)  
 ACE inhibitor 8 (17.4) 16 (19.5)  
 Calcium channel blocker 4 (8.7) 15 (18.3)  
 Beta-blocker 11 (23.9)  33 (40.2)  
 Diuretics 7 (15.2)  24 (29.3)  
* P-value in bold indicated the significance (p< 0.05)  
§  p value obtained from t- test without tithe assumption of equal variance; other p-values were obtained from chi-square test 
¶ Patient-self-reported history of disease 







Table 3. CVD categories within CVD group 
 
               Category    n [%] 
  Coronary Heart Disease 24 (29.3) 
 Cerebrovascular Disease 12 (14.6) 




 Rhythm Disorders 23 (28.0) 
  Pacemaker 12 (14.6) 
  Valvular Disease 6 (7.3) 
 Subclinical Atherosclerosis 2 (2.4) 
  Thoracic or Abdominal Aortic Aneurysm 2 (2.4) 





Table 4. Lipid profiles and Classification of atherosclerotic cardiovascular disease (ASCVD) risk 
assessment and cardiometabolic disease 
 
         Variable 
non-CVD (n = 46) 
n [%]  
CVD (n =82) 
n [%]  
P Value 
Fasting Glucose Level    0.28 
  Normal (<100 mg/dl) 14 (35.8) 14 (21.9)   
 Prediabetes (100~125 mg/dl) 22 (55) 37 (57.8)  
  Well-Controlled DM (126~153 mg/dl) 3 (7.5) 12 (18.8)   
 Moderate Controlled (154~183 mg/dl) 1 (2.5) 1 (1.6)  
Total Cholesterol Type     0.07 
 Normal 28 (75.5) 61 (91)  
  Borderline 8 (21.6) 6 (9)   
 High 1 (2.7) 0 (0)  
Triglycerides Type     0.25 
 Normal 32 (86.5) 64 (94.1)  
  Borderline 4 (10.8) 4 (5.9)   
 High 1 (2.7) 0 (0)  
Triglycerides Severity     0.19 
 Normal 32 (86.5) 63 (94)  
  Hypertriglyceridemia 5 (13.5) 4 (6)   
VLDL Type   0.32 
  <30 32 (86.5) 62 (92.5)   
 >30 Elevated 5 (13.5) 5 (7.5)  
HDL Type     0.07 
 Low 5 (13.5) 23 (34.3)  
  Borderline 19 (51.4) 27 (40.3)   
 High (Optimal) 13 (35.1) 17 (25.4)  
cLDL Type     <0.01 
 Normal 18 (48.6) 58 (87.9)  
  Above Normal 14 (37.8) 7 (10.6)   
 Borderline High 4 (10.8) 1 (1.5)  




cLDL Severity   <0.01 
  Normal 18 (48.6) 58 (86.6)   
 Borderline 18 (48.6) 9 (13.4)  
  Hypercholesterolemia 1 (2.7) 0 (0)   
Chol/HDL Ratio   0.08 
  Normal 33 (89.2) 66 (98.5)   
 Borderline 2 (5.4) 1 (1.5)  
  Risk 2 (5.4) 0 (0)   
LDL/HDL Ratio   0.02 
  Normal 21 (91.3) 61 (100)   
 Risk 2 (8.7) 0 (0)  
ASCVD Risk Type     <0.01 
 Low 6 (16.2) 2 (3)  
  Borderline 3 (8.10) 4 (6)   
 Intermediate 16 (43.2) 15 (22.4)  
  High 12 (32.4) 46 (68.7)   
Cardiometabolic Stage   <0.01 
  1 13 (30.2) 0 (0)   
 2 11 (25.6) 0 (0)  
  3 12 (27.9) 0 (0)   
 4 7 (16.3) 82 (100)  
* P-value in bold indicated the significance in the chi-square test (p< 0.05)  




Table 5.  Prevalence of peri-implant disease and implant-related characteristics 
 
Variable 











Peri-implant healthy 4 (8.7) 75 0  8 (9.8) 100 0 
Peri-implant mucositis 16 (34.8) 75 0  21 (25.6) 76.2 9.5 
Peri-implant: bone loss beyond initial physiological 
bone remodeling 
       
 > detectable bone loss 26 (56.5) 84.6 15.4  53 (64.6) 77.8 18.9 
 Moderate to severe (≥2 mm bone loss) 14 (30.4)* 71.4 28.6  40 (48.8)* 75 25 
 Severe (>4 mm bone loss) 8 (17.4) 62.5 37.5  14 (17.1) 50 50 
BOP        
 <33% 7 (15.2)    10 (12.2)   
 33-66% 21 (45.7)    28 (34.1)   
 >66% 18 (39.1)    44 (53.7)   
Suppuration 7 (15.2)    7 (8.5)   
Implant prosthesis        
 Fixed prosthesis 45 (97.8)    1 (2.2)   
 Overdentures 70 (85.4)    12 (14.6)   

















Table 6. Periodontal health variables 
 
 
P-value in bold indicated the significance in the chi-square test (p< 0.05)  
* Based on the Classification of 2017 World Workshop 




Table 7. Age-stratified analyses for the prediction of CVD 
 
 
         Variable 
non-CVD (n = 45) 
n [%] 
CVD (n =72) 
n [%] 
Odds ratio P Value 
Periodontal health   23 (51.1) 17 (23.6) 
3.4 <0.01 
Chronic periodontitis 22 (48.9) 55 (76.4) 
 Severity    < 0.01 
 Stage 1 10 (41.7) 3 (4.5)  
 
 Stage 2 7 (29.2) 52 (78.8) 
 Stage 3 2 (8.3) 3 (4.5)  
 Stage 4 5 (20.8) 8 912.1) 
 Extent    0.04 
 Localized 12 (54.5) 26 (29.1) 
2.9  
  Generalized 10 (45.5)  39 (70.9) 
 Grade*     0.01 
 Grade A 7 (31.8) 3 (5.4)   
  Grade B 12 (54.5) 48 (87.3)   
 Grade C 3 (13.6) 4 (7.3)   
      Grade¶ (combined hsCRP)    0.16 
 Grade A 5 (12.5)  2 (2.9)   
 Grade B 9 (19.6)  18 (25.7)   
 Grade C 26 (56.5) 50 (71.4)   
Teeth loss number     
  < 5 teeth 23 (51.1) 25 (30.5)  
<0.01   5-10 teeth 18 (40) 28 (34.1)  
 > 10 teeth 4 (8.9) 29 (35.4)  
Fully Edentulism  1 (2.2) 10 (12.2)   0.05 
Maintenance frequency     
  Episodic 23 (51.1) 46 (59.7) 




¶ p-value in bold indicated statistically significance (p< 0.05) 
§ p-value indicated borderline significance 
* adjusted for gender, smoking, hypertension, and family history of heart attack 
Moderate to severe peri-implantitis= radiographic bone loss≥2 mm and BOP± suppuration 
Table 8. Multivariate logistic regression model for the prediction of CVD 
 
 










Moderate to severe peri-implantitis  
only adjusted for gender 
 
Model 
Moderate to severe peri-implantitis* 
 OR (95% CI) p-value  OR (95% CI) p-value 
All population 2.3 (1.1 to 5.0)   0.04¶  2.0 (0.8 to 4.6) 0.12 
(range 43-91 y)      
      
40-60 y 2.7 (0.12 to 59.1) 0.54  1.0 0.49 
60-80 y 2.5 (0.9 to 6.5)    0.06 §  1.9 (0.6 to 5.6) 0.24 
>80 y 2.1 (0.4 to 11.4) 0.38   3.4 (0.5 to 24.5) 0.24 
        Variable Unadjusted OR (95% CI) 
Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI) 
Model 1 Model 2 Model 3 
Peri-implantitis     
 Detectable bone loss 1.48 (0.71 to 3.11)    
 Bone loss≥ 2mm 2.18 (1.02 to 4.67) 1.64 (0.58 to 4.7) 1.67 (0.54 to 5.15) 1.14 (0.35 to 3.75) 
 Bone loss> 3mm 1.39 (0.63 to 3.05)    
 Bone loss> 4mm 0.98 (0.38 to 2.54)    
Age  1.05 (1.0 to 1.11) 0.96 (0.87 to 1.06) 1.1 (1.03 to 1.14) 
Hypertension  0.84 (0.29 to 2.44) 0.71 (0.23 to 2.2) 0.64 (0.2 to 2.12) 
Family history of heart attack  2.35 (0.84 to 6.57) 2.66 (0.90 to 7.88) 2.39 (0.8 to 7.12) 
Smoking     
 Non-smoker  referent referent referent 
 Ever-smoker   5.19 (1.71 to 15.7) 5.76 (1.83 to 18.2) 3.81 (1.12 to 13.0) 
cLDL level  0.12 (0.04 to 0.38) 0.11 (0.03 to 0.39) 0.12 (0.03 to 0.45) 
ASCVD risk type     
 Low   referent  
 Borderline   5.9 (0.24 to 149.6)  
 Intermediate   4.55 (0.24 to 84.0)  
 High   33.9 (0.93 to 1385.5)  




SD: standard deviation 





Table 10. Stratified analysis of Serum CRP 
SD: standard deviation 
*denotes the statistically significant difference (P<0.05) from Kruskal-Wallis test 
 
 













AUC: Area under the curve; CI: confidence interval 
 non-CVD  CVD  
Biomarker  mean(SD)  Median  mean (SD)  Median p-
value 
IL-1𝛽  (pg/ml) 58.4± 103.0 17.9  97.0± 136.8 33.6 0.02* 
IL-6 (pg/ml) 191.3± 362.4 6.1  267.3± 570.6 27 0.09 
MMP-8 (pg/ml) 33.2± 101.1 13.2  29.1± 54.5 13.2 0.66 
OPG (pg/ml) 1044.5± 846.6 758.2  1287.8± 925.1 968.4 0.09 
TNF-𝛼  (pg/ml) 56.5± 152.1 6.9  104.7± 161.7 31.6 <0.01* 
CRP (mg/L) 7.7± 4.2 9.2  6.4± 3.5 6.5 0.11 
Fibrinogen (mg/dl) 62.3± 35.7 50.9  86.2 ± 61.5 70.0 0.03* 




Statin therapy (No) non-CVD 8.7±3.9 9.9 0.09 
 CVD 6.7±3.8 6.1  
Statin therapy (Yes) non-CVD 5.3±4.2 4.7 0.51 
 CVD 6.2±3.4 6.6  
Normal LDL non-CVD 6.3±4.0 5.8 0.93 
 CVD 6.3±3.6 6.4  





 CVD 7.5±3.5 6.7  
 AUC 95% CI p-value 
Serum IL-1𝛽 0.63 0.50-0.76 0.08 
Serum IL-6 0.64 0.50-0.79 0.06 
Serum MMP-8 0.53 0.43-0.43 0.31 
Serum OPG 0.58 0.40-0.73 0.31 
Serum TNFa 0.67 0.56-0.78 0.02* 
Serum hsCRP 0.44 0.51-0.79 0.41 







Table 12. Serum diagnostic ability of serum biomarkers 
 
   Marker level      
Biomarker Group Threshold 
High Low Sensitivit
y 
Specificity OR 95% CI p-value 
IL-1𝛽 CVD 19.3(pg/ml) 41 29 58.6% 63.2% 2.4 1.1-5.4 0.03* 
 non-CVD  14 24      
IL-6 CVD 20.7(pg/ml) 38 16 50.3% 57.9% 1.6 0.7-3.6 0.23 
 non-CVD  16 22      
MMP-8 CVD 13.2(pg/ml) 15 56 21.1% 35.6% 1.2 0.4-3.2 0.74 
 non-CVD  7 31      
OPG CVD 897(pg/ml) 49 8 86% 45.2% 5.0 1.8-14.1 <0.01* 
 non-CVD  17 14      
TNF-𝛼 CVD 14.6(pg/ml) 42 28 60.0% 65.8% 2.9 1.3-6.6 0.01* 
 non-CVD  13 25      
hsCRP CVD 6.8(mg/L) 28 34 45.2% 43.3% 0.6 0.3-1.6 0.6 





55.1% 58.3% 1.7 0.8-3.9 0.19 
 non-CVD  15 21      
† denotes the significant difference between groups from ꭓ2 test (P< 0.05) 
Figure 1. Receiver operating characteristic (ROC) curve for the diagnostic ability of serum biomarkers 








































non-CVD + mod/sev PI* 64.2±111.8 194.6±350.3 66.6±171.8 839.6±382.4 103.5±242.2 6.8±3.9 74.3±50.0 
CVD + Healthy implant 142.2±184.4 352.2±655 42.8±76.8 1322.1±956.3 149.7±182.9 7±3.5 89.5±80.7 
CVD + mod/sev PI* 60.7±62.9 191.6±479.8 16.8±11.2 1262±915.7 64.6±129.8 5.9±3.5 83.3±39.0 
 p-value 0.03† 0.52 0.1 0.38 0.03† 0.22 0.13 
non-CVD + HI + Healthy perio 71.3±120.1 237.6±443.1 15.8±9.8 1184.2±1156.9 40±80.7 7.9±5.2 51.3±16.8 
non-CVD + HI + Periodontitis 22.2±8 87.5±132 15.9±6.2 1057.8±590.3 15.1±12.1 8.6±2.7 63.6±31.8 
non-CVD + mod-sev PI *+ Healthy 
perio 
53.8±50.8 546.1±474.8 29.8±28.7 758.2±- 300.5±486.6 3.64±- 68.9±15.8 
non-CVD + mod-sev PI* + 
Periodontitis 
78.4±135.6 110.7±272.9 93.7±219.4 891.6±449.9 51.2±104.7 7.7±4 84.4±61.5 
CVD + HI + Healthy perio 174±234.4 249.6±404.9 55.3±115.6 1720±1356 196.8±244.2 5.5±3.6 66.8±39.3 
CVD + HI + Periodontitis 98.3±81.1 383.5±775.4 41.3±62.3 1219.8±711.7 94.8±97.5 7.3±3.4 85.9±53.9 
CVD + mod -sev PI* + Healthy perio 51.5±58.2 127.4±194.7 13.2±0 721.1±218.5 85±108.5 3.7±4.2 88.7±49.9 
CVD + mod-sev PI* + Periodontitis 58.3±60.2 192.6±509.4 16.9±11.8 1321.9±941.4 58.3±131.7 6.3±3.3 79.6±39 
 p-value 0.45 0.19 0.89 0.04† 0.1 0.31 001† 
non-CVD+ Healthy implant 17.9±0 3.1±0 13.2±0 526.5±107.4 6.9±0 7.6±3.3 56.1±15.2 
non-CVD+ PID 60.7±105.6 201.8±369.7 34.3±103.8 1080.2±864.3 59.2±155.9 7.7±4.4 62.7±36.7 
CVD+ Healthy implant 224.9±270.6 488±673 82.6±134.5 1630.3±1025.6 209.1±204.2 8.5±2.4 13.6±14.7 
CVD+ PID 84.0±126.4 240.8±559 23.1±34.7 1261.4±922.6 93.1±153.9 6.2±3.6 80.6±42.3 
 p-value 0.22 0.51 0.23 0.14 0.12 0.19 0.01† 
ASCVD low risk 50.2±88 104.7±253.5 24.3±20.7 976±1123.1 32.3±71.9 9.1±3.8 67.7±47.7 
ASCVD borderline risk 81.2±82.4 150±207.6 15.5±6 1449.1±688.3 70.3±91.7 5.1±3.2 11.7±56.7 
ASCVD intermediate risk 79.7±114.4 226±582.7 47.9±118.9 962.3±697.9 91.7±175.2 6.5±3.8 56.0±23.7 
ASCVD high risk 94.4±144.8 292±530.3 24.9±50.1 1331.1±997.1 100.8±170 6.9±3.8 85.8±63.8 
 p-value 0.8 0.72 0.52 0.04† 0.72 0.3 0.02† 
*mod-sev PI: moderate to severe peri-implantitis with bone loss≥ 2mm 
† denotes the significant difference between groups from Kruskal-Wallis test (P< 0.05) 
Healthy perio= healthy periodontium  
PID= peri-implant disease, including mucositis and peri-implantitis 
ASCVD risk assessment: low-risk (<5%); borderline risk (5% to 7.4%); intermediate risk (7.5% to 19.9%); high risk (≥20%) 
All serum biomarkers were measured in the unit of pg/ml, except hsCRP in mg/L and fibrinogen in mg/dl 
 
 
Table 14. PICF biomarkers profiles between non-CVD and CVD group 
 
 non-CVD  CVD  
Biomarker  mean(SD)  Median  mean (SD)  Median p-value 
CRP (pg/ml) 227.9±236.2 181.5  169.9± 171.1 130.7 0.27 
IL-17 (pg/ml) 2.5±1.6 1.7  3.0 ±5.4 1.7 0.39 
IL-1𝛽 (pg/ml) 129.8±94.0 118.6  101.8±110.7 55.0 0.045 
IL-6 (pg/ml) 5.3±14.8 1.1  2.4±5.1 1.1 0.25 
Il-8  (pg/ml) 283.8±143.4 306.1  275.9±147.6 293.4 0.77† 
MMP-8 (mg/L) 3144.9±985.1 3203.6  3333.2±1123.4 3476.8 0.17 
MPO (pg/ml) 1135.6±608.8 1070.1  1284.1±781.1 1231.2 0.27 
OPG (pg/ml) 82.4±127.7 35.2  78.1±200.5 15.5 0.11 
TIMP-2 (pg/ml) 1365.9±698.2 1352.6  1278.8±741.3 1220.4 0.52† 
TNF-𝛼( pg/ml) 8.3±3.2 6.6  11.3±8.0 6.6 0.05 
VEGF (pg/ml) 101.0±116.7 66.0  74.7±101.0 43.2 0.11 
PGE2 (pg/ml) 137.7±171.1  75.4  112.9±126.0 82.6 0.72 
SD: standard deviation 
Q1: 25th percentile, Q2: Median; Q3: 75th percentile 
*Bold denotes the statistically significant difference (P<0.05) from Kruskal-Wallis test 









95% CI 0.49-0.69 
p-value 0.08 










Table 15. PICF biomarkers profiles 
 
 CRP IL-17 IL-1𝛽 IL-6 IL-8 MMP-8 MPO OPG TIMP-2 TNF-𝛼 VEGF PGE2 
HI 192.6±172.9 2.6±2.1 115.9±97.3 2.7±5.3 275.3±138.9 3117.3±1044.1 1206.2±705.2 78±194.8 
 





















139.7±171.3 2.6±1.4 52.5±81.0 1.1±0.0 202.2±157.2 2468.5±1368.5 943.6±739.2 42.0±56.0 757.7±684.9 9.8±3.7 55.3±76.1 94.9±63.5 
CVD+ 
PID 




0.27 0.11 0.01* 0.5 0.07 0.02* 0.41 0.25 0.02* 0.27 0.26 0.85 
HI 121.3±151.6 2.9±1.5 59.1±97.6 1.1±0.1 171.0±158.0 2210.7±1328.6 1101.9±829.2 35.9±47.4 688.8±655.7 8.9±3.3 51.1±62.0 80.3±61.4 




0.2 003* 0.01* 0.44 0.01 <0.01* 0.44 0.81 <0.001* 0.89 0.22 0.28 
HI 121.1±151.6 2.8±1.5 59±97.6 1.1±0.1 171±158 2210.7±1328.6 1101.9±829.2 35.9±47.4 688.8±655.7 8.9±3.3 51.1±62 80.3±61.4 
MU 226.1±184.9 2.7±2.6 129.8±83.7 3.2±6.4 308±122.3 3452.3±813 1187.7±761.7 66.7±117.1 1397.8±526.3 10.4±6.4 91.9±83.8 133.6±12
1.4 








HI: healthy implant; Mod-sev PI: moderate to severe per-implantitis (with bone loss ≥2mm); PID: peri-implant disease 
(including peri-implant mucositis and peri-implantitis); MU: peri-implant mucositis 
*Bold denotes the statistically significant difference (P<0.05) from Kruskal-Wallis test 
 
 
Table 16. GCF biomarkers profiles 
 




























































p-value 0.6 0.64 0.01* 0.76 0.31 0.5 0.62 0.23 0.98 0.06 0.07 









Table 17. GCF comparison between CVD and control at different sites collecting GCF 
 








































































































































































p-value 0.12 0.18 0.48 0.79 0.03* 0.3 0.84 0.27 0.27 0.5 0.19 











teeth in periodontitis 
patients) 
AUC 0.64 
95% CI 0.51-0.78 
p-value 0.04 





TNF-𝛼 (healthy teeth in 
periodontitis patients) 
AUC 0.66 
95% CI 0.54-79 
p-value 0.05 







Figure 4. ROC analysis of GCF OPG for predicting moderate to severe peri-implantitis 
 
OPG (periodontitis teeth 
in periodontitis patients) 
AUC 0.62 
95% CI 0.50-75 
p-value 0.06 





OPG (healthy teeth in 
periodontitis patients) 
AUC 0.66 
95% CI 0.54-79 
p-value 0.05 









Table 18. Microbial compositions in the order of most commonly found between two groups  
 
Total non-CVD group CVD group 
Taxonomy in species % Taxonomy in species % Taxonomy in species % 
Fusobacterium nucleatum* 13.7 Fusobacterium nucleatum* 16.1 Fusobacterium nucleatum* 12.3 
Streptococcus mitis-oralis-sanguinis* 4.5 Streptococcus mitis-oralis-sanguini*s 4.0 Streptococcus mitis-oralis-sanguinis* 4.7 
Parvimonas micra 3.4 Parvimonas micra 3.7 Streptococcus intermedius 3.3 
Streptococcus intermedius 3.4 Streptococcus intermedius 3.4 Parvimonas micra 3.3 
Veillonella parvula 3.1 Veillonella parvula 3.0 Veillonella parvula 3.2 
Prevotella oris 2.9 Prevotella oris 2.5 Prevotella oris 3.1 
Unknown species 2.1 Porphyromonas endodontalis 2.3 Haemophilus parainfluenzae 2.7 
Campylobacter gracilis 1.9 Campylobacter gracilis 2.0 Unknow species  2.3 
Haemophilus parainfluenzae 1.9 Clostridiales sp31630 1.9 Campylobacter gracilis 1.9 
Porphyromonas endodontalis 1.8 Alloprevotella tannerae 1.8 Neisseria macacae-mucosa-sicca 1.8 
Neisseria macacae-mucosa-sicca 1.6 Unknown species 1.8 Porphyromonas gingivalis 1.7 






Table 19. Microbial compositions in the order of most commonly found in subgroups  
 
non-CVD group CVD group 
Healthy implant Peri-implantitis Healthy implant Peri-implantitis 
Taxonomy in species % Taxonomy in species % Taxonomy in species % Taxonomy in species % 
Fusobacterium nucleatum* 13.2 Fusobacterium nucleatum* 17.0 Fusobacterium nucleatum* 13.8 Fusobacterium nucleatum* 11.5 
Streptococcus mitis-oralis-
sanguinis 







Streptococcus intermedius 4.2 Streptococcus intermedius 3.1 Streptococcus intermedius 3.6 Veillonella parvula 3.9 
Parvimonas micra 3.8 Streptococcus mitis-oralis-sanguinis 3.1 Unknown species 3.3 Prevotella oris 3.6 
Veillonella parvula 3.4 Veillonella parvula 2.9 Neisserria macacae-mucosa-sicca 3.0 Parvimonas micra 3.5 
Porphyromonas endodontalis 2.6 Prevotella oris 2.5 Parvimonas micra 2.8 Streptococcus intermedius 3.2 
Prevotella oris 2.6 Unknown species 2.3 Haemophilus parainfluenzae 2.3 Haemophilus parainfluenzae 2.9 
Alloprevotella tannerae 2.4 Oribacterium sp33063 2.1 Streptococcus sangiunis 2.3 Campylobacter gracilis 1.9 
Streptooccis mutans 2.3 Clostridiales sp31630 2.0 Porphyromonas gingivalis 2.2 Unknown species 1.8 











% in total amount Non-CVD +HI Non-CVD +PI CVD +HI CVD +PI 
Fusobacterium nucleatum 13.2 17.0 13.8 11.5 
Porphyromonas gingivalis 1.8 0.5 2.2 1.4 
Tannerella forsythia 0.6 0.9 1.3 0.6 
Prevotella intermedia 0.5 1.6 0.2 0.5 
Treponema denticola 0.4 0.5 0.4 0.4 




Table 21. Bacteria DNA counts P. gingivalis, T. forsythia, and F. nucleatum obtained by RT-qPCR between 
non-CVD and CVD group 
 
 P. gingivalis T. forsythia F. nucleatum 
 Mean±SD Mean±SD Mean±SD 
Healthy 3.9 ± 3.4E+07 1.3 ± 1.5E+07 4.3 ± 9.4E+07 
CVD 5.3 ± 6.5+07 1.5 ± 2.0+07 2.1 ± 3.0E+07 
 p-value 0.88 0.25 0.47 
non-CVD + Healthy implant 2.3± 1.3E+07 0.8 ± 1E+07 4.1± 11.2E+07 
non-CVD + Peri-implantitis(detectable bone 
loss) 
4.5± 3.8E+07 1.6 ± 1.7E+07 4.6± 7.7E+07 
CVD + Healthy implant 6.5± 8.8E+07 1.7±3.3E+07 1.6± 1.5E+07 
CVD + Peri-implantitis (detectable bone loss) 4.8± 5.5E+07 1.4 ± 2.6E+07 2.6± 3.8E+07 
 p-value 0.97 0.26 0.38 
non-CVD + HI + Healthy perio  1.6 ± 0.8E+07 0.8± 1.1E+07 5.8 ± 13.8E+07 
non-CVD + HI + Periodontitis 3.7E+07  0.9 ± 0.7E+07 1 ± 1.2E+07 
non-CVD + PI + Healthy perio  0.4E+07 2.2 ± 2.6E+07 3.2± 5.7E+07 
non-CVD + PI + Periodontitis 5.2± 3.7E+07 1.3 ± 1E+07 6.2 ± 9.8E+07 
CVD + HI + Healthy perio  2.1± 1.9E+07 0.8 ± 0.6E+07 1.1 ± 0.8E+07 
CVD + HI + Periodontitis 12.1±10E+07 2.3 ± 4.2E+07 2.1 ± 1.8E+07 
CVD + PI + Healthy perio  8.6± 3.8E+07 2.1  ± 4.1E+07 0.6 ± 0.6E+07 
CVD + PI + Periodontitis 4.7± 5.8E+07 1.3 ± 2.3E+07 3.2 ± 4.3E+07 







Table 22. Bacteria DNA counts of P. gingivalis, T. forsythia, and F. nucleatum obtained by RT-qPCR of 
different peri-implant disease 
 
 




 Mean±SD Mean±SD Mean±SD 
Healthy implant 5.8 ± 8E+07 1.3 ± 2.7E+07 2.8 ± 7.8E+07 
Peri-implantitis with detectable bone loss 4.8 ± 5.2+07 1.5 ± 2.2+07 3.5 ± 5.9E+07 
 p-value 0.97 0.83 0.12 
Healthy implant 5.2± 7.1E+07 1.3± 2.4E+07 3.2± 7.9E+07 
Peri-implantitis with ≥ 2 mm bone loss 4.9± 5.3E+07 1.6 ± 2.5E+07 3.2± 3.6E+07 
 p-value 0.55 0.97 0.04* 
Healthy 5 ± 6.8E+07 1.2 ± 2.3E+07 2.9 ± 7.3E+07 
Peri-implantitis with > 3 mm bone loss 5 ± 5.4E+07 2 ± 2.8E+07 4.1 ± 4.2E+07 
 p-value 0.51 0.29 0.02* 
Healthy 4.4 ± 5.9E+07 1.1 ± 2.1E+07 3.1 ± 7.2E+07 
Peri-implantitis with > 4 mm bone loss 6.9 ± 6.4E+07 3.2 ± 3.3E+07 3.8 ± 2.7E+07 
 p-value 0.12 0.01* 0.03* 
Healthy implant 1.6 ± 0.85E+07 0.33 ± 0.12E+07 0.64 ± 0.68E+07 
Peri-implant mucositis 6.4 ± 8.5E+07 1.6 ± 3E+07          3.6 ± 9.2E+07 
Peri-implantitis (detectable bone loss) 4.8 ± 5.2E+07 1.5 ± 2.3E+07 3.6 ± 5.9E+07 
 p-value 0.55 0.15 0.02* 
Healthy implant 1.6 ± 0.85E+07 0.33 ± 0.12E+07 0.64 ± 0.68E+07 
Peri-implant disease 5.2 ± 6.2E+07 1.5 ± 2.5E+07 3.6 ± 7.3*E+07 
 p-value 0.8 0.28 0.05* 
All analyses were dony by Kruskal-Wallis nonparametric test compared the median (Normality Shapiiro-Wilk test< 0.05)  





























Maintenace DM Smoking 




Healthy Single 5 mm Y 8 Regular No Never 























Multiple 10 mm N >15 Episodic No Ex- (>30y) 











Single 6 mm N >5 Regular Diabetes 
 
Never 






Figure 5. The prominent species among case and control groups with significant difference 
 
 
Figure 6.  Absolute abundance among the "Case" and "Control" group 
 
















Figure 8. Beta-diversity among non-CVD (Healthy) and CVD group 
Principal Coordinate Analysis of unweighted Unifrac distance of microbial communities associated to the non-CVD (Healthy) 
and CVD group. Each dot represents an individual samples plots according to its microbial profile at genus level.  
 
Figure 9. Mean value of absolute abundance in gene copies/µl among subgroups of healthy implants and 
















Figure 10. LEFse analysis among 4 subgroups between case and control groups case (with or without 
peri-implantitis)    
 
  
  *Group A= non-CVD + healthy implant  
    (No significant standout abundant species in the LEFse comparison: Group B= non-CVD + peri-implantitis; Group C= CVD + 
healthy  




Figure 11. LEFse analysis between case and control groups case (among subjects with peri-implantitis) 









Figure 12. LEFse analysis between case and control groups case (among subjects with peri-implant 
disease) 
Group A= non-CVD+ Peri-implant disease    Group B= CVD+ Peri-implant disease       





























Group1: PPD≤ 3mm; Group2: 
PPD: 4-6 mm; Group 3: ≥ 7 mm 
 
 
Figure 17. Microbial diversity among different peri-implant pocket depths in the cladogram and number 
of observed species  






























                     
 
Group I: presence of suppuration; Group II: absence of suppuration 
 
 
Figure 20. Beta Diversity metrics of microbial profile between presence/absence of suppuration 
Figure 21. Microbial abundance and diversity between dentate and edentulous subjects 
Group 1: dentate patients with healthy implant (red); Group 2: dentate patients with peri-implantitis (green) 






Figure 22. Cladogram of the distribution of microbial community in dentate/edentulous patients 
Group 1: dentate patients with healthy implant (red); Group 2: dentate patients with peri-implantitis (green) 






Figure 23. Simpson reciprocal index plot of alpha diversity (within sample) among peri-implantitis sites 





Figure 24. Microbial beta-diversity among pockets with peri-implantitis with simultaneous presence of 
different severity of periodontitis  










Table 25. Comparison of PICF biomarkers between peri-implant disease and healthy implants 
 
*Bold denotes the statistically significant difference (P<0.05) from Kruskal-Wallis test 
 
Figure 25. ROC analysis of PGE-2 prediction ability for a more severe peri-implantitis (bone loss >3 mm) 
 
Biomarker Healthy                   Moderate to severe peri-implantitis  
 Mean (SD) Q1 Q2 Q3 
 
Mean (SD) Q1 Q2 Q3 
p-
value 
CRP 191.6±171.9 30 130.7 332.5  185.6±215.1 142.4 245.6 419.6 0.48 
IL-17 2.5±2.1 1.7 1.7 2.7  3.1±5.9 1.7 1.8 4.3 0.3 
IL-1𝛽 117±99.5 21.1 102.8 179.2  99.5±111.9 53.8 168.1 248.2 0.19 
IL-6 2.6±5.3 1.1 1.1 1.1  3.9±12.5 1.1 1.1 1.6 0.31 




2562.9 3302 3768.5 
 
3387.2±1125.8 3476 4131.1 4636.8 0.09 
MPO 1205.2±695.9 600.1 1111.5 1721.3  1267.1±769.4 1265.1 1854.1 2392.8 0.7 
OPG 78.1±192.3 4.7 29.1 57.3  72.6±139.6 10.3 70.5 194.9 0.22 
TIMP-2 1282.3±704.5 787.5 1243 1743.6  1267.7±777.4 1262.2 1799.5 2461.4 0.78 
TNF-𝛼 9.7±5.6 6.6 6.6 10.9  10.6±7.6 6.6 12.6 16.9 0.8 
VEGF 87.5±104.9 32.6 55 93.9  73.6±105 35.3 90.9 165.6 0.04* 
PGE2 120.5±136.4 45.3 81.7 150.9  134.1±109.5 64.3 102.5 187.2 0.17 
Biomarker Healthy  Periimplant disease  
 Mean (SD) Q1 Q2 Q3 
 
Mean (SD) Q1 Q2 Q3 
p-
value 
CRP 121.1±151.6 15.8 74.1 214.8  195±195.1 38.1 151.7 309.7 0.19 
IL-17 2.8±1.5 1.7 2.2 3.7  2.8±4.5 1.7 1.7 1.9 0.3 
IL-1𝛽 59.1±97.6 3.5 8.1 76.4  113.5±105.3 21.6 75.1 178.8 0.02* 
IL-6 1.1±0.1 1.1 1.1 1.1  3.4±9.8 1.1 1.1 1.1 0.49 
IL-8 171±158 17.3 114.4 301.615  287.1±142.9 176.9 304 395.2 0.02* 
MMP-8 2210.7±1328.6 1227.2 2176.6 3459.7  3331.6±1022 2721.4 3445.5 3952.5 0.01* 
MPO 1101.9±829.2 499.1 731.7 1664.8  1246.2±721.4 606.5 1199.5 1809.1 0.44 
OPG 35.9±47.4 4.8 24.9 47.1  79.2±176 4.7 21.3 83 0.88 
TIMP-2 688.8±655.7 161.2 435.3 1069.7  1329.7±722.1 777.8 1292.5 1799.5 <0.01* 
TNF-𝛼 8.9±3.3 6.6 6.6 10.6  10.2±6.8 6.6 6.6 11.9 0.85 
VEGF 51.1±62 10.6 40.1 61.9  83.8±107.6 23.2 50.6 95.6 0.30 











95% CI 0.50-0.75 
p-value 0.04 












95% CI 0.51-0.72 
p-value 0.03 













PICF Biomarker AUC 95% p-value 
CRP 0.59 0.43-0.76 0.31 
IL-17 0.37 0.20-0.55 0.16 
IL1-b 0.70 0.52-0.90 0.03 
IL6 0.54 0.38-0.70 0.75 
IL8 0.70 0.53-0.89 0.03 
MMP-8 0.73 0.56-0.90 0.01 
MPO 0.53 0.34-0.71 0.79 
OPG 0.49 0.40-0.63 0.92 
TIMP-2 0.74 0.58-0.90 0.01 
TNF-𝛼 0.49 0.33-0.67 0.95 
VEGF 0.57 0.42-0.73 0.41 
PGE2  0.69 0.54-0.84 0.04 
 
 



























Sensitivity Specificity OR 
p-
value High Low 






    






    






    






    
MMP-8 PID 
3422.8 





    
IL-1𝛽 PID 
71.6 





    
TIMP-2 PID 
1243.0 





    
PGE2 PID 
90.3 





    
*Bold denotes the statistic significant difference (P<0.05) from ꭓ2 test 
Mod-sev PI= moderate to severe peri-implantitis (bone loss≥ 2mm) 


















Table 27. ROC analysis of targeted species  
 
 
 P. gingivalis  T. forsythia  F. nucleatum 
 AUC p-value  AUC p-value  AUC p-value 














Severe peri-implantitis (>4mm) 0.95 0.01  0.95 0.01  0.95 0.01 










*Bold denotes the statistic significant difference (P<0.05) from ꭓ2 test; Mod-sev PI= moderate-severe peri-implantitis (bone 

























Table 29. Combined diagnostic ability of selected PICF biomarkers and targeted bacterial species 
 
Biomarker Group Sensitivity Specificity OR p-value 
P. gingivalis Mod-sev PI 56.1% 55.6% 1.6 0.35 
 Healthy implant     
T. forsythia Mod-sev PI 63.9% 54.7% 2.1 0.08 
 Healthy implant     
F. nucleatum Mod-sev PI 69% 57.7% 3.0   0.02* 
 Healthy implant     
P. gingivalis Peri-implant disease 53.8 100% 8.1 0.17 
 Healthy implant     
T. forsythia Peri-implant disease 56.6% 100% 16.9  0.01* 
 Healthy implant     
F. nucleatum Peri-implant disease 57.1% 81.8% 6.0  0.02* 




*Bold denotes the statistic significant difference (P<0.05) from ꭓ2 test 
OR= odds ratio 






Biomarker Group Sensitivity Specificity OR p-value 
P. gingivalis + MMP-8 Mod-sev peri-implantitis 59% 50% 1.5 0.54 
 Healthy implant     
P. gingivalis + IL-1𝛽 Mod-sev peri-implantitis 43% 55% 1.0 0.96 
 Healthy implant     
P. gingivalis + TMP-2 Mod-sev  peri-implantitis 53% 53% 1.3 0.65 
 Healthy implant     
T. forsythia + MMP-8 Mod-sev  peri-implantitis 71% 53% 2.9 0.08 
 Healthy implant     
T. forsythia + IL-1𝛽 Mod-sev  peri-implantitis 65% 47% 1.7 0.38 
 Healthy implant     
T. forsythia + TMP-2 Mod-sev  peri-implantitis 65% 53% 2.1 0.23 
 Healthy implant     
F. nucleatum + MMP-8 Mod-sev  peri-implantitis 77% 63% 5.6  0.01* 
 Healthy implant     
F. nucleatum + IL-1𝛽 Mod-sev  peri-implantitis 82% 52% 5.0  0.02* 
 Healthy implant     
F. nucleatum + TMP-2 Mod-sev  peri-implantitis 77% 55% 4.0  0.03* 
 Healthy implant     
P. gingivalis + MMP-8 Peri-implant disease 43% 55% 6.89 0.11 
 Healthy implant     
P. gingivalis + IL-1𝛽 Peri-implant disease 47.4% 100% 6.3 0.11 
 Healthy implant     
P. gingivalis + TMP-2 Peri-implant disease 53.8% 100% 5.8 0.14 
 Healthy implant     
T. forsythia + MMP-8 Peri-implant disease 63% 100% 18.5 0.05* 
 Healthy implant     
T. forsythia + IL-1𝛽 Peri-implant disease 63.3% 100% 18.7 0.01* 
 Healthy implant     
T. forsythia + TMP-2 Peri-implant disease 57.4% 100% 12.1 0.03* 
 Healthy implant     
F. nucleatum + MMP-8 Peri-implant disease 58.5% 100% 18.2 0.01* 
 Healthy implant     
F. nucleatum + IL-1𝛽  Peri-implant disease 66.7% 100% 21.6 <0.01* 
 Healthy implant     
F. nucleatum + TMP-2 Peri-implant disease 61.9% 100% 14.5 0.02* 
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Chapter IX. Supplemental Tables and Figures 
 
 
Supplemental Figure 1. Theoretical microbial composition of the ZymoBIOMICS® Microbial Community 



















Supplemental Figure 2. Comparison between non-CVD and CVD group at the Phylum level 
Supplemental Figure 3. Comparison between non-CVD and CVD group at the Class level 
 ★ denotes the periodontitis-associated bacterial classes; red font indicated the percentage in the microbial community of    
      individual Class among CVD group compared to the black font (healthy group) 
Supplemental Table 1. Composition of Taxonomy at the Class level  
 
 non-CVD CVD 
k__bacterial;p__Firmicutes;c__Bacilli 17.42% 19.34% 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia 17.40% 16.30% 
k__Bacteria;p__Fusobacteria;c__Fusobacteriia 18.47% 15.18% 
k__Bacteria;p__Actinobacteria;c__Actinobacteria 10.78% 12.66% 
k__Bacteria;p__Firmicutes;c__Clostridia 10.65% 8.82% 
k__Bacteria;p__Firmicutes;c__Negativicutes 6.12% 6.24% 
k__Bacteria;p__Proteobacteria;c__Betaproteobacteria 3.09% 4.11% 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria 1.07% 3.78% 
k__Bacteria;p__Proteobacteria;c__Epsilonproteobacteria 2.66% 2.55% 
None;Other;Other 1.80% 2.25% 
k__Bacteria;p__Actinobacteria;c__Coriobacteriia 2.14% 2.01% 
k__Bacteria;p__Spirochaetae;c__Spirochaetes 1.93% 1.92% 
k__Bacteria;p__Saccharibacteria;c__NA 1.03% 1.42% 
k__Bacteria;p__Synergistetes;c__Synergistia 1.81% 1.32% 















  Group A= non-CVD + healthy implant  
  Group B= non-CVD + peri-implantitis 
  Group C= CVD + healthy implant 









































Supplemental Figure 5. LEfSe analysis of 
















≥ 7 mm 
 







































Group A (purple): Peri-implantitis +Stage 1 periodontitis 
Group B (green): Peri-implantitis +Stage 2 periodontitis 
Group C (yellow): Peri-implantitis +Stage 3 periodontitis 
















Serum hsCRP, a downstream marker for inflammation, has been considered as an important predictor for 
CVD risk. It was categorized as low risk (hsCRP<1 mg/L), intermediate risk (1-3 mg/L) and high risk (>3 
mg/L) by (Greenland et al. 2010)). Serum hsCRP levels over 10 mg/L is correlated with an over 4% global 
risk of developing a fatal CVD in 10 years (Cozlea et al. 2013). hsCRP is produced in the liver in response 
to infection or inflammatory disease, such as RA, systemic lupus erythematous (SLE), or cancer. 
Phenotypes that predispose accelerated atherosclerosis including metabolic syndrome, visceral obesity, and 
insulin resistance were significantly associated with elevated levels of hsCRP (Yousuf et al. 2013). Adipose 
tissue, a significant source of IL-6, may explain the robust association between hsCRP and obesity (Buckley 
et al. 2009). It has been widely accepted that low grade systemic inflammation, and consequently an 
elevated hsCRP, contributes to an elevated risk of CVD (Teeuw et al. 2014). A meta-analysis of 54 long-
term prospective studies reported the CRP concentration was linearly associated with several risk factors 
and inflammatory markers, and nearly log-linearly with the risk of ischemic vascular disease and non-
vascular mortality (Kaptoge et al. 2010). However, its predictive value has been proved to be limited. First, 
a lack of a causative relationship between CRP and CHD has been suggested by animal and human genetic 
data (Elliott et al. 2009; Koike et al. 2009; Dehghan et al. 2011). A meta-analysis of 46,557 patients with 
CHD and 147,861 controls confirmed the null association among CRP-related genotypes, traditional risk, 
and risk of CHD (Wensley et al. 2011). Secondly, the variability among individuals (genetic 
polymorphisms, sex, ethic, BMI, hypertension, periodontal disease, environmental pollutant burden, and 
lifestyle) and technical sensitivity could contribute to the massive heterogeneity. In the current 
investigation, CRP was not associated with CVD occurrence, even among those with LDL-C < 130 mg/dl, 
for whom the use of hsCRP has been advocated by some (Detrano et al. 2008; Blankstein et al. 2011). 
Additional analysis showed that it was positively correlated with the LDL-C level in the linear regression 
model (Slope: 2.0, p=0.03, R-square= 0.07) (Supplemental Figure 8). It is understandable since CRP 
directly bonds to atherogenic oxidized LDL cholesterol and is present within lipid-laden plaques (Libby et 
al. 2010). The current result that average levels of hsCRP was higher in the non-CVD group may be 
correlated to the higher percentage of participants with abnormal LDL-C.  


























PICF non-significant biomarkers 
Although only a trend of higher OPG and IL-6 at peri-implant diseased sites was noted, a notably increased 
concentration isolated from the GCF among patients with periodontitis was found in the current 
investigation. A significantly higher peri-implant concentration of bone remodeling biomarkers (RANK, 
OPG, and RANKL) has been reported in peri-implantitis sites(Duarte et al. 2009a; Rakic et al. 2014). 
RANKL and RANKL/OPG ratio have been documented to be higher in the periodontitis pockets as well 
(Rakic et al. 2013). It has been reported that a significantly higher level of pro-inflammatory cytokine IL-6 
is found at peri-implantitis sites (Yaghobee et al. 2014). It is in agreement with a meta-analysis that IL-6 is 
found higher in sites with peri-implantitis than in peri-implant mucositis sites (Ghassib et al. 2019). 
However, some had also reported that IL-1𝛽 and IL-6 are not significantly different between healthy 




elevated IL-8 in sites with peri-implantitis and periodontitis, which was in line with the previous 
findings(Venza et al. 2010). Similar studies, which have shown IL-8 secretion is highly correlated with IL-1 
secretion (Payne et al. 1993) as well as the clinical manifestation of periodontal diseases (Tsai et al. 2002; 
Giannopoulou et al. 2003) can also support our results. Future studies are needed to clearly define the 
relationship. Lastly, VEGF was found to be higher in peri-implant mucositis than peri-implantitis in the 
present study, which may be related to the erythma of soft connective tissue affected by the mucositis or 
infection. VEGF increases vascular permeability and extravasation of plasma proteins to facilitate the 
migration and oxidation of the augmented inflammatory cells. It has been reported to be lower in peri-
implantitis samples, and positively correlated to the inflammatory infiltrates (Cornelini et al. 2001). 
 
 
 
 
